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ABSTRACT  
Myogenesis, or skeletal muscle formation, begins during embryogenesis and 
involves the proliferation of myoblasts followed by their exit from the cell-cycle to 
differentiate and form myotubes. This formation of skeletal muscle is a complex 
process involving many genes and various signalling pathways. Mighty is a novel 
myogenic gene discovered at AgResearch by the Functional Muscle Genomics 
(FMG) group in a genetic screen performed on the muscle of myostatin null and 
wild-type mice. It was found that heavily muscled mice, lacking myostatin, had 
increased expression of the mighty gene. This gene was found to be conserved, with 
cognates found in mammals, amphibians, teleosts, and arthropods. Mighty was 
found to be expressed in a variety of tissues, but only skeletal muscle showed 
increased mighty mRNA expression in myostatin null mice, indicating the specific 
regulation of mighty by myostatin in skeletal muscle (Marshall, 2005). 
 
The aim of this study was to characterise the mighty protein and examine its role in 
myogenesis to elucidate mighty’s function. To undertake this study, antibodies 
specific for the full-length mighty protein and antibodies specific for a peptide 
region of mighty were characterised. Results using these antibodies, showed 
endogenous mighty, from myoblasts, to be a low-abundant, nuclear protein which 
shows a mobility of ~52 kDa in SDS gels, different to that of recombinant mighty 
protein. The mobility difference of endogenous mighty compared to recombinant 
mighty appears to be due to phosphorylation and may involve other post-
translational modifications. In agreement, the determined isoelectric point (~5.7) of 
endogenous mighty also appears to be the result of phosphorylation. Interestingly, 
52 kDa mighty was not detected in muscle extracts, but a ~30 kDa protein was 
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specifically detected, indicating multiple forms, and subsequent roles, for mighty 
protein. Mass spectrometry (MS) was also performed for further characterisation of 
the mighty protein and possible post-translational modifications. Although hits were 
achieved with both recombinant mighty proteins, endogenous mighty MS analysis 
was not accomplished due to its low-abundance. 
 
The function of the mighty protein in myoblasts was investigated during 
proliferation and differentiation. The results indicate that proliferating myoblasts 
have low levels of mighty in G0 and increased levels in G1/S during the cell 
cycle. This differential expression of mighty may involve cell cycle exit at the 
G1/S phase. Differentiation results showed mighty to be upregulated before 
MyoD during differentiation, placing mighty very early in the differentiation 
hierarchy. This agrees with previous results by Marshall (2005) which showed 
mighty to upregulate MyoD through IGF-II expression. Enhanced differentiation 
was also seen in double muscle bovine myoblasts concomitantly with increased 
mighty expression. 
 
In conclusion, mighty appears to be a post-translationally modified protein that 
plays an early role in myogenic differentiation. This role in differentiation 
appears to be upstream of MyoD through the upregulation of IGF-II and may be 
linked to cell cycle exit in the G1 phase of the cell cycle.  
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CHAPTER ONE 
LITERATURE REVIEW  
In this literature review, an overview of skeletal muscle physiology and 
structure is outlined, followed by a description of the process of myogenesis 
from embryo formation. This is followed by a review on myostatin including its 
structure, function, and signalling. The current information on the novel 
transcription factor mighty and its relationship to myostatin will then be given. 
Finally, the aims of this thesis will be stated along with the possible 
implications. 
 
1.1 Skeletal Muscle 
Skeletal muscle is responsible for voluntary body movement by generating 
active force through the application of the skeletal system. Muscle cells highly 
specialised for contraction enable this movement to occur. These muscle cells 
originate during embryogeneis, with skeletal muscle developing through their 
terminal differentiation and fusion of myoblasts into multi-nucleate myotubes, 
forming the contractile muscle fibre. Within each muscle fibre is the myofibril 
protein structure which is responsible for force production. Each fibre is 
associated with a population of self-renewing satellite cells capable of dividing 
and fusing with muscle fibres. This fusion is an essential part of muscle growth 
and repair.  
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1.1.1 Skeletal muscle structure 
Skeletal muscle consists of bundles of muscle fibres called fascicles. The 
fascicles are separated by connective tissue, the perimysium, and between each 
individual muscle fibre is a layer of connective tissue, the endomysium. 
Enclosing the entire muscle is another layer of connective tissue, the 
epimysium. Each muscle fibre is a multi-nucleated muscle cell containing 
smaller subunits called myofibrils which are the functional contractile units of 
skeletal muscle (Fig 1.1). Study of the myofibrils under the electron microscope 
shows the striated structure of their sarcomere units. The sarcomeres primarily 
consist of two types of protein structures: thick filaments and thin filaments. 
The thick filaments consist mainly of myosin protein whereas the thin filaments 
are mainly composed of the proteins: actin, troponin, and tropomyosin. The 
thick filaments interact with the thin filaments by myosin extensions (cross-
bridges). Muscle contraction is accomplished by the ATP-powered rotation of 
the cross-bridges along the thin filaments. The sarcomere unit is defined as the 
distance between adjacent Z-disks. The Z-disks (Zwischen-Scheibe, meaning 
interim disc) bisect the I-bands (isotropic bands). The I-bands are the region 
which consists of thin filaments only. The H-zone (Hele-Scheibe zone) contains 
only thick filaments and the central M-line (middle line). The A-band 
(anisotropic) includes the H-zone and dark portions either side which show the 
regions where the thick and thin filaments interdigitate. During contraction each 
sarcomere unit is shortened by the pulling of the thin filaments towards the 
centre of the sarcomere, the combined shortening of each sarcomere unit results 
in muscle contraction. 
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Figure 1.1  Skeletal muscle structure 
A, Skeletal muscle consists of bundles of muscle fibres called fascicles. Each 
muscle fibre is a multi-nucleated muscle cell composed of smaller subunits 
called myofibrils; B, Myofibrils are composed of highly organised repeated 
units called sarcomeres; C The sarcomeres primarily consist of two types of 
protein structures: thick filaments and thin filaments (Adapted from Randall et 
al., 1997).  
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1.2 Myogenesis and the embryonic origin of muscle 
Muscle formation, or myogenesis, is an important part of embryo development. 
During embryogenesis, skeletal muscle forms in the embryo from clusters of 
cells known as the somites (Christ & Ordahl, 1995). The somites produce two 
distinct muscle populations: the cells that form the axial and trunk musculature, 
and a second migratory cell population that establishes the muscles of the 
developing limbs (Fig 1.2). The somites are found on either side of the neural 
tube and notochord after segmenting from the paraxial mesoderm (Ludolph & 
Konieczny, 1995). Signals from the neural tube and notochord induce the 
somites to differentiate into the dermomyotome (dorsal) and sclerotome 
(ventral). The dermomyotome can be further divided into the hypaxial and 
epaxial dermomyotome. Progenitor cells delaminate from the hypaxial 
dermomyotome and migrate to the limb bud. Once in the limb bud, the cells 
proliferate, express myogenic determination factors, and differentiate into 
skeletal muscle of the body wall and limbs. Cells originating from the epaxial 
dermomyotome give rise to skeletal muscle of the back. The sclerotome 
provides the cells of the vertebrae and ribs (Hawke & Garry, 2001).  
 
In the developing embryo, the delamination and migration of muscle progenitor 
cells from the somites to the limb buds depends on the presence of c-met. This 
tyrosine kinase receptor can interact with its ligand, hepatocyte growth 
factor/scatter factor (HGF/SF) which is produced by non-somitic mesodermal 
cells, therefore showing the migratory route (Dietrich et al., 1999). 
Transcription of the c-met gene occurs through the Pax3 transcription factor 
(Epstein et al., 1996). Tajbakhsh et al. (1997) have shown Pax3 mutant mice to 
be without limb muscles due to no cell migration from the hypaxial  
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Figure 1.2  Somitogenesis 
Somites differentiate dorsally into the dermomyotome and ventrally into the 
sclerotome. The dermomyotome gives rise to a subpopulation of cells termed 
the myotome. The medial region of the myotome gives rise to back musculature 
(epaxial muscles), while myogenic precursor cells produced from the lateral 
myotome give rise to limb and body wall muscles (hypaxial muscles). NT 
(neural tube); NC (notochord); DML (dorsal-medial lip); VLL (ventral-lateral 
lip) (Adapted from Pownall et al., 2002). 
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dermomyotome occurring. Like Pax3, Lbx1 is a homeo-domain-containing 
transcription factor implicated in the migration of cells from the somites. In 
Lbx1 mutants, muscle progenitor cells delaminate from the dermomyotome but 
stay close to the somites and may adopt other cell fates (Schafer & Braun, 
1999). Signals from Wnt proteins, originating from the dorsal ectoderm and 
neural-tube, direct multipotent cells of the somites to become committed muscle 
cells. Wnt6, produced by the surface ectoderm, has been implicated in the 
activation of the Pax3 gene (Fan et al., 1997).  
 
1.2.1 Myogenic regulatory factors 
Early in embryogenesis, the myogenic determination genes are not yet activated 
in cells migrating from the somites. It is only when the muscle precursor cells 
are within the limb bud that Pax3 and Lbx1 expression ceases and myogenic 
regulatory factors (MRFs) and the MEF2 family of myocyte enhancer-binding 
factors begin to be expressed (Lassar et al., 1994; Tajbakhsh & Buckingham, 
1994). MRFs are muscle-specific gene regulatory factors that include the 
important sub-group of the MyoD family of regulatory proteins, consisting of 
MyoD, myogenin, myf-5, and MRF4. The hierarchical expression of the MRF 
genes initiates a cascade of events that result in muscle cell differentiation. 
Myf-5 and MyoD expression can be seen in cultured myoblasts and continue to 
be expressed after differentiation. Myogenin is essential for differentiation and 
is expressed after myoblast fusion. MRF4 is expressed only after muscle 
differentiation and appears to be responsible for maintaining the differentiated 
state (Rudnicki et al., 1993).  
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The MRFs share a region of homology with two functionally significant 
domains, the helix-loop-helix (HLH) domain and the basic region domain, 
forming the basic-helix-loop-helix (bHLH) characteristic of this large family of 
transcriptional activators. The HLH domain facilitates dimerisation with 
members of the ubiquitously-expressed E-protein family. This family includes 
E12, E47, E2-2, E2-5, HEB, ITF1 and ITF2. Any of the E-proteins can form 
functional heterodimers with the MRFs, but the most prevalent heterodimers in 
myotube extracts contain E12. The basic region of the MRFs, which contains 
positively charged amino acids, mediates specific binding to DNA. The 
MRF/E-protein heterodimers bind to DNA consensus CANNTG (E-box) found 
in several muscle-specific promoters (Lassar et al., 1991). The genes encoding 
the MRFs also contain an E-box suggesting the MRFs regulate their own and 
each-others transcription. Interactions of MRFs with DNA can be prevented by 
members of a family of HLH factors known as ‘inhibitor of binding’ or Id 
proteins. The Id proteins lack a basic region, so when bound to MRF proteins 
the complex is unable to bind to DNA and activate transcription. Id proteins 
appear to inhibit myogenesis during embryonic development and their down-
regulation then enables myogenesis to proceed by allowing MRFs to bind to the 
DNA of target genes (Wang et al., 1992).  
 
The MyoD family of basic helix-loop-helix factors play a vital role in 
embryogenesis; no skeletal muscle forms in MyoD/Myf5 double mutants due to 
the absence of the precursor myoblast population (Rudnicki et al., 1993). Also, 
both MyoD and Myf-5 have the ability to convert non-muscle cells to muscle 
cells when ectopically expressed in various cell-types from different germ layer 
origins (Choi et al., 1990). In gene knock-out experiments, mice that were null 
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for either Myf-5 or MyoD genes developed normally (Rudnicki et al., 1992). 
MyoD knockout mice exhibited a 3-4 fold increase in Myf-5 expression which 
continued longer than usual. Normally, Myf-5 expression is significantly 
reduced at day 12 of gestation when MyoD mRNA first appears, suggesting that 
MyoD represses Myf-5 expression. The increase and prolongation of Myf-5 
expression suggests Myf-5 compensated for the lack of MyoD. Whereas in 
Myf-5 knock-outs, the development of muscle was delayed until the normal 
expression of MyoD proceeded (Braun et al., 1994). These results indicated that 
the function of MyoD and Myf-5 may be redundant. However, Kitzmann et al. 
(1998) showed that cells positive for differentiation markers expressed MyoD 
and not Myf-5 whereas myoblasts that remain undifferentiated expressed Myf-5 
and not MyoD. MyoD and Myf-5 also have very different expression profiles 
during the cell cycle. MyoD is low in G0 and high in G1 whereas Myf-5 is high 
in G0 and low in G1. In vivo, this difference in MyoD and Myf-5 is thought to 
be particularly relevant to the muscle stem cells known as satellite cells. These 
satellite cells are normally quiescent, do not express differentiation markers, 
and can reenter the cell cycle in response to released mitogens. In single cell 
analysis, subsets of freshly isolated satellite cells were found to express either 
MyoD of Myf-5 and after 24 h these cells could co-express both MyoD and 
Myf-5 (Cornelison & Wold, 1997). Therefore, expression of Myf-5 alone may 
allow satellite cells to proliferate and self-renew before either returning to 
quiescence or forming proliferative myoblasts through the up-regulation of 
MyoD resulting in myoblasts capable of proliferation and differentiation into 
myotubes (Sabourin & Rudnicki, 2000). 
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Myogenin has been shown to be an essential intermediate in myogenesis (Hasty 
et al., 1993; Nabeshima et al., 1993). Myogenin knockout mice initially develop 
normally with somites forming myotome, dermatome, and sclerotome. Muscle 
differentiation is initiated, but very few myofibres are formed. This difference 
between the myogenin knockouts and the wild-types becomes more pronounced 
as development continues with large amounts of un-differentiated myoblasts 
present in mutant muscle (Venuti et al., 1995). The myogenin knock-out mice 
have decreased levels of transcripts for some muscle-specific proteins, 
including muscle creatine kinase, myosin heavy chain, the alpha and gamma 
subunits of the acetylcholine receptor and MRF4. Normal amounts of MyoD 
transcripts were present, showing that MyoD appears to act upstream of 
myogenin (Hasty et al., 1993). 
 
Throughout muscle repair and growth, satellite cells repeat the MRF expression 
patterns seen during embryonic development. Quiescent satellite cells do not 
express MRFs until muscle injury or growth stimulation, they then proliferate 
and express Myf-5 and MyoD (Cornelison & Wold, 1997; Cooper et al., 1999). 
Myogenin expression follows and is associated with fusion and terminal 
differentiation (Smith et al., 1994; Yablonka-Reuveni & Rivera, 1994). Recent 
insights have been made into the extensive array of genes that are amplified by 
the MRFs and MEF2 using chromatin immunoprecipitation (ChIP) assays and 
genome-wide location analysis (Blais et al., 2005). These include transcription 
factors involved in stress-response pathways, synapse formation, and synaptic 
transmission. These results highlight the wide range of roles by MRFs in 
muscle development, growth, and repair. 
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1.2.2 MEF2 family 
The myocyte enhancer factor-2 (MEF2) family is another class of muscle 
transcription factors which belong to the ‘MCM1 agamous deficiens and serum 
response factor’ (MADS) superfamily of DNA binding proteins (Ludolph & 
Konieczny, 1995). In mammals, the MEF2 family consists of four distinct 
genes: MEF2A, MEF2B, MEF2C, and MEF2D. Proteins in the MADS 
superfamily all contain a 56-amino acid motif referred to as the MADS box 
which is responsible for DNA binding and protein dimerisation. MEF2 factors 
also contain a unique 29-amino acid sequence known as the MEF2 domain 
which indicates further DNA specificity. In contrast to the MRF genes, the 
MEF2 genes are expressed in a wide range of cell types, including skeletal, 
cardiac, and visceral muscle, also brain and neural crest cell derivatives 
(Edmondson et al., 1991). MEF2 isoforms from alternative mRNA splicing and 
post-transcriptional modifications may regulate cell-specific expression and 
activity of different MEF2 proteins.  
 
Muscle gene activation by MRFs is dependent on their association with MEF2 
family members. The MEF2 factors work with the MRFs and are unable to 
activate muscle specific genes alone. MEF2 DNA binding sites are often 
positioned near MRF binding sites (E-boxes) in the regulatory regions of many 
muscle genes. Independent expression of myogenin or MyoD in 10T1/2 
fibroblasts induces MEF2 DNA binding activity (Cserjesi & Olsen, 1991). 
Reciprocally, MEF2 proteins can activate expression of myogenin and MRF4 
genes, this interaction is specific as the MADS domain of MEF2 recognises 
MRF bHLH domains but not non-myogenic bHLH domains (Naidu et al., 1995; 
 11
Cheng et al., 2002). Therefore, the MRF and MEF2 protein interactions occur 
only in the context of muscle development (Ludolph & Konieczny, 1995).  
 
1.2.3 Myogenesis and the cell-cycle 
Proliferating myoblasts go through orderly stages of the cell-cycle (Fig 1.3) to 
enable the accurate duplication of DNA and the subsequent division into two 
identical daughter cells. The cell-cycle, or cell division cycle, can be divided 
into four distinct stages: during the synthesis phase (S phase) the genetic 
material is copied faithfully: in the mitosis phase (M phase) the duplicated 
chromosomes are equally separated to the two daughter cells. The phases in 
linking the S and M phases are gap-1 (G1) preceding the S phase and gap-2 
(G2) preceding the M phase. The gap phases represent important regulatory 
check points and preparation for the following stage. During early G1, with the 
appropriate signals, a cell may withdraw from the cell-cycle into a resting 
quiescent state known as G0 or they may proceed to terminally differentiate.  
 
Various classes of cellular proteins are responsible for the orderly transition 
from one cell-cycle phase to another. The main class of cell-cycle proteins 
identified are the cyclin dependent kinases (CDKs). Members of this family of 
serine/threonine protein kinases are activated at specific stages of the cell-cycle, 
appearing and disappearing during the cell-cycle phases in a controlled cyclic 
manner (Sherr, 1996). Transcriptional activation of the cyclin genes and 
ubiquitin-mediated degradation of the cyclin proteins allows for a fast turnover 
of the CKIs. The acitivities of the cyclins are also regulated by binding of CDK-
inhibitors (CKIs) and through phosphorylation and dephosphorylation (Elledge, 
1996).  
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Figure 1.3  The cell cycle 
Signals promoting and inhibiting the different phases of the cell cycle as well as 
checkpoints monitoring the accurate completion of every phase of the cell cycle 
(Adapted from Tessema et al., 2004). 
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The order and timing of the cell-cycle transition is critical and so mammalian 
cells have various checkpoints to ensure correct progress of the cell-cycle. In 
addition to halting defective cell-cycles, checkpoints also enable repair of DNA 
damage. An important cell-cycle check-point is near the end of the G1 phase 
and is termed the G1/S transition check-point or restriction point. The G1/S 
checkpoint represents a commitment to cell division; beyond this checkpoint 
cells proceed with the cell-cycle until completion and no longer respond to 
external signals. The low level of the CDKs combined with their suppression by 
high CKI activity halt the cell-cycle in early G1 and during G0 (Sherr, 2000). 
The result of inactive CDKs is hypophosphorylated retinoblastoma protein (Rb) 
which remains bound to E2F. The E2F family of proteins enable transcription 
of genes important for the replication of DNA and are only active when free 
from Rb. Specific extracellular signalling initiates the proliferation pathway and 
D-type cyclins start to accumulate due to increased expression and reduced 
proteolysis (Molinari, 2000). The partially active CDK4/6-cyclin D complex is 
then formed which becomes fully active through phosphorylation by CDK-
activating kinase (CAK). The CDK4/6-cyclin D holoenzyme then 
phosphorylates Rb which leads to the release of E2F transcription factors 
resulting in the transcription of genes required for S-phase entry (Tessema, 
2004). Rb is inactivated by active CDK2/cyclin E and CDK4/6-cyclin D 
holoenzymes, and allows the induction of more E2F-responsive genes to initiate 
DNA replication. This further induces more CDK2/cyclin E as a positive 
feedback loop. CDK2/cyclin E facilitates degradation of inhibitory factors like 
Hct1 and p27 (Sherr, 2000). Without appropriate mitogenic signals and in the 
presence of anti-proliferative factors (e.g. myostatin) or defective DNA, cell-
cycle progression is halted at the G1/S checkpoint. The two families of CKI 
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active at the G1/S checkpoint are the INK4 family and the CIP/KIP family. The 
INK4 family members (p15INK4b, p16INK4a, p18INK4c, and p19INK4d) function only 
at G1 to inhibit CDK4/6. Whereas the CIP/KIP family (p21CIP1, p27KIP1, and 
p57KIP2) are active as CKIs in all four cell-cycle phases (Sherr & Roberts, 
1999). 
 
During S phase the precise duplication of the cell’s chromosomes occurs and 
begins when the required proteins reach a sufficient level. In eukaryotes, 
replication of DNA is initiated at multiple sites of the chromosome 
simultaneously. As in G1, the progression during S phase is regulated by CDK 
activities. Various phosphorylations by CDK2/cyclin A of components of DNA 
replication machinery are important for the initiation of DNA replication. 
Levels of cyclin A accumulate during S phase and are rapidly degraded via 
ubiquitin-mediated proteolysis before metaphase. Cyclin A synthesis is 
activated by E2F, in a negative feedback loop, E2F activity is inhibited by 
CDK2/cyclin A through phosphorylation of the E2F heterodimerisation partner 
DP1 (Yam et al., 2002). After all of the chromosomes have been duplicated, the 
cell is then able to enter G2. 
 
At the G2 phase of the cell-cycle, the cell contains two copies of its 
chromosomes. Before the process of cell-division can start, checks are made to 
ensure all genetic material and important cellular structures are accurately 
duplicated. Arrest of the cell-cycle can occur at G2 if there is damage to the 
DNA and/or incomplete duplication has resulted during the S phase. In addition 
to its role in G1 arrest, p21 is also involved with inducing G2 arrest through 
blocking the interaction between CDC25C phosphatase and ‘proliferation cell 
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nuclear antigen’ (PCNA). The p21 gene is a direct target of transcriptional 
activation by the tumour suppressor protein, p53. The p53 protein functions to 
maintain genomic integrity by inducing cell-cycle arrest and subsequently 
repair or apoptosis (Stewart et al., 2003). 
 
The M phase is a combination of mitosis and cytokinesis. Mitosis, the 
segregation of the cellular components, is induced by increased activity of the 
CDK1/cyclin B holoenzyme, also known as ‘mitosis promoting factor’ (MPF). 
Activated MPF phosphorylates proteins important for chromosome 
condensation, motor and microtubule-binding proteins, nuclear envelope 
breakdown, spindle assembly, and centrosome separation (Nigg, 2001).  
 
The cell-cycle stages outlined above are tightly linked processes that are 
regulated by growth factor activity. The arrest of the cell cycle is essential 
during skeletal muscle differentiation and occurs before S phase during the G1 
phase of the cell cycle (Nadal-Ginard, 1978; Clegg et al., 1987). Once 
terminally differentiated, myotubes are generally unable to reenter the cell cycle 
in response to growth factors. The antagonism that exists between proliferation 
and differentiation requires that signalling pathways driving proliferation are 
suppressed to allow the initiation of differentiation and the maintenance of 
permanent cell cycle withdrawal in myotubes (Kitzmann et al., 1998).  
 
During myogenesis, these different cell cycle regulatory pathways can be 
inhibited or reinforced by muscle-specific regulators of the MyoD family. 
MyoD, Myf-5, myogenin, and MRF4 are essential transcriptional activators 
throughout myogenesis, but only MyoD and Myf-5 are expressed in 
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proliferating myoblasts (Weintraub et al., 1993). In C2C12 myoblasts, MyoD 
has been shown to be absent in G0, peaking in mid G1, and falling to a 
minimum level at G1/S and reaugmenting from S to M. Conversely, Myf-5 is 
high in G0, decreasing during G1, then increasing at the end of G1 and 
maintained until mitosis (Kitzmann et al., 1998). In muscle cells, cell-cycle 
arrest occurs through MyoD activation of p21 and p57 (Wei & Paterson, 2001). 
The enhancement of p21 expression by MyoD ultimately leads to the 
downregulation of cdks. Additionally, MyoD interacts with the 
hypophosphorylated form of Rb, possibly maintaining Rb in its active form 
resulting in the inhibition of the E2F-mediated transcription of genes required 
for S phase (Gu et al., 1993). MyoD has also been shown to downregulate 
cyclin B expression (Chu et al., 1997), which inhibits MPF phosphorylation of 
various proteins involved in mitosis. Therefore, variations in MyoD levels 
and/or activity appear to affect the balance between proliferation and 
differentiation. This has been observed in various cell lines, where the ability of 
cells to differentiate appears strongly linked to the level of MyoD expression 
(Montarras et al., 1996). 
 
The known positive inducers of myogenesis such as insulin like growth factors, 
thyroid hormones, and retinoic acid, enhance both MyoD expression and 
muscle differentiation (Pinset et al., 1988; Florini et al., 1991a; Carnac et al., 
1992; Albagli-Curiel et al., 1993). Myostatin, a negative regulator of 
myogenesis, inhibits MyoD activity and expression resulting in the inhibition of 
myoblast differentiation (Langley et al., 2002). These results imply that a 
minimal level of MyoD must be reached before differentiation can be achieved. 
In agreement, MyoD levels have been observed to vary considerably in the 
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nuclei of proliferating myoblasts by immunocytochemistry, whereas MyoD was 
seen to be homogeneously high in myotubes (Tapscott et al., 1988). Therefore, 
the induction of differentiation at a specific stage of the cell cycle, presumably 
G1, appears to be related to the level of MyoD (Kitzmann, 1998). 
 
1.2.4 Differentiating myoblasts 
Andres and Walsh (1996) described skeletal myogenesis as a highly ordered 
process of temporally separable events that direct the transition from the 
proliferative myoblast to the terminally differentiated myotube. They showed 
that in vitro myogenesis involves at least four temporally separable events: first, 
the entry of myoblasts into the differentiation pathway as indicated by the 
initiation of myogenin expression; second, the irreversible withdrawal from the 
cell cycle as indicated by the expression of p21; third, phenotypic 
differentiation as indicated by the induction of MHC; fourth, the fusion of 
differentiated myocytes to form myotubes. Myogenin expression signals a cells 
entry into differentiation, and later, structural protein expression is seen 
including MHC. The significance of myogenin can be observed in myogenin 
KO mice, where deficient transcripts of various muscle-specific proteins are 
seen, including MHC, muscle creatine kinase, the alpha and gamma subunits of 
the acetylcholine receptor, and MRF4 (Hasty et al., 1993). Once a myoblast 
enters the differentiation pathway, expresses myogenin and exits the cell cycle, 
it is committed to become skeletal muscle and is unable to proliferate. 
 
Two temporally distinct waves of myotube formation occur during the 
differentiation of muscle cells. Early forming primary myotubes provide a 
support for the later forming secondary myotubes which can be distinguished 
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from primary myotubes by their relatively smaller diameter (Wigmore & 
Dunglison, 1998). Primary and secondary myotubes grow by cell fusion, 
eventually separating and maturing into primary and secondary muscle fibres. 
These two types of muscle fibre express different myosin heavy chain (MHC) 
isoforms. It is the MHC protein isoforms that are partly responsible for the fast 
(primary, glycolytic) and slow (secondary, oxidative) contraction rates 
displayed by these fibres (Schiaffino & Reggiani, 1996). A proportion of 
primary and secondary fibres switch fibre type, resulting in the distribution of 
fibres seen in adult skeletal muscle. 
 
The differentiation of myoblasts is controlled by various factors. In cell culture 
experiments, differentiation of cells can be induced by depriving cycling 
myoblasts of serum, which results in the formation of committed myotubes. 
Myoblast differentiation is often viewed as being negatively regulated by 
medium components referred to as “mitogens.” However, stimulators of 
differentiation also occur, for example, members of the ‘insulin growth factor’ 
(IGF) family. IGF-II is a secreted factor required for terminal differentiation 
and is up-regulated upon transfer to low-serum differentiation medium. IGF-II 
can also enhance differentiation when added to media (Florini et al., 1991a).  
 
1.2.5 Muscle stem cells and regeneration  
The postnatal growth, repair, and maintenance of skeletal muscle are 
accomplished by a sub-population of myogenic precursor cells known as 
satellite cells. Muscle satellite cells are located between the basal lamina and 
the muscle fibre, and are often referred to as muscle stem cells (Seale & 
Rudnicki, 2000). In mice, satellite cells account for 30% of the sublaminar 
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muscle nuclei at birth, dropping to approximately 5% in adults (Bishoff, 1994). 
This decrease appears to be due to the contribution of satellite cells during 
postnatal muscle growth and development (Gibson & Schultz, 1983; Seale and 
Rudnicki, 2000). Adult satellite cells are mitotically quiescent until activated in 
response to various stimuli, including injury, exercise, stretching, and electrical 
stimulation (Rosenblatt et al., 1994; Grounds, 1998). Quiescent satellite cells 
can be identified by their expression of various cell markers. These include 
transcription factors such as Myf5 (Beauchamp et al., 2000), Pax7 (Seale et al., 
2000), and myocyte nuclear factor (MNF) (Garry et al., 1997): also expressed 
are the surface markers M-cadherin (Irintchev et al., 1994), CD34 (Beauchamp 
et al., 2000), and c-met (Cornelison & Wold, 1997).  
 
Expression of Myf5, MNF, and M-cadherin show commitment to the myogenic 
lineage (Beauchamp et al., 2001). M-cadherin is thought to be specifically 
involved in the adhesion of satellite cells to the basal lamina of the muscle fibre, 
and the migratory response of satellite cells to stimuli (Hawke and Garry, 
2001). The induction of MNF and Pax7 are thought to induce the specification 
of satellite cells through the restriction of other differentiation programs. Pax7 
is present in quiescent and proliferating satellite cells and its importance is seen 
with pax7-null mice which are devoid of satellite cells (Seale et al., 2000). 
CD34 is a transmembrane glycoprotein also expressed on endothelial cells and 
hematopoietic stem cells, while c-met is a receptor for HGF and is thought to be 
involved in satellite cell activation. 
 
Activated satellite cells become myogenic precursor cells, which are able to 
proliferate prior to differentiating and fusing with existing or new muscle fibres 
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(Grounds & Yablonka-Reuveni, 1993; Bischoff, 1994; Seale et al., 2000). The 
exact process of satellite cell activation is unclear, but is thought to involve the 
interaction between ‘hepatic growth factor’ (HGF) and its receptor c-met in 
quiescent satellite cells. HGF is believed to be released from the basal lamina 
after damage, and to be produced by myofibres in response to physiological 
stimuli. The expression of MyoD and/or Myf5 follows satellite cell activation 
and the subsequent generation of muscle progenitor cells (Seale and Rudnicki, 
2000). Other growth factors, such as IGF-1, have been implicated in the 
proliferation of muscle progenitor cells into differentiated myotubes (Adams, 
1998). Signalling between cells of the immune system and satellite cells are 
also thought to facilitate muscle regeneration (Seale & Rudnicki, 2000). 
Leukocytes infiltrating the site of injury express the surface protein VLA-4, a 
coreceptor for the cell adhesion molecule VCAM1, which is expressed by 
quiescent satellite cells. Macrophages, along with the phagocytosis of necrotic 
debris, also release mitogens such as ‘leukaemia inhibitory factor’ (LIF) and 
interleukin-(IL-6) which stimulate the proliferation of cultured myoblasts 
(Kurek et al., 1996). 
 
A further population of pluripotent stem cells or side population (SP) cells have 
recently been identified. These SP cells can be isolated by fluorescence-
activated cell sorting (FACS) through dye exclusion (Gussoni et al., 1999; Seale 
et al., 2000). Both Myf5 and CD34 are not expressed by SP cells but they do 
express the early haematopoietic stem cell marker Sca1 (Beauchamp et al., 
2000; Buckingham, 2001). SP cells transplanted from bone marrow or muscle 
have been found to participate in muscle regeneration. However, only muscle-
derived stem cells appear to give rise to muscle satellite cells (Gussoni et al., 
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1999). It is not clear whether SP cells are the same as satellite cells, satellite cell 
precursors, or a different population of cells (Seale et al., 2000).  
 
1.2.6 Growth factors involved in myogenesis 
Growth factors play important roles at various stages during myogenesis. The 
determination, proliferation, differentiation, and regeneration of cells during 
myogenesis involves factors such as fibroblast growth factors (FGFs), insulin-
like growth factors (IGFs), scatter factor/hepatocyte growth factor (SF/HGF), 
and transforming growth factor β (TGF-β) superfamily members.  
 
Fibroblast growth factors (FGFs) and their ligands are essential factors during 
embryonic development and contribute to the formation of skeletal, smooth, 
and cardiac muscle (Scata et al., 1999). The FGF family shares a conserved 120 
amino acid core region and consists of 23 members (Dickson et al., 1989; 
Fernig & Gallagher, 1994; Kirikoshi et al., 2000). Signalling by FGF members 
is mediated through FGF ligand interactions with four specific tyrosine kinase 
receptors to activate various signalling pathways (Partanen et al., 1992; Fernig 
and Gallagher, 1994; Scata et al., 1999; Nishimura et al., 2000). With cultured 
muscle cells, FGFs have been found to stimulate proliferation and inhibit 
differentiation (Linkhart et al., 1980; Linkhart et al., 1981; Olwin & Hauschka, 
1986; Rando & Blau, 1994). 
 
Insulin-like growth factors (IGFs) are strongly involved in the formation and 
maintenance of skeletal muscle. They are secreted factors which elicit their 
effect by binding to cell surface receptors to initiate signalling cascades. The 
three known receptors that bind IGFs are the insulin, IGF-I, and IGF-II 
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receptors. The insulin receptor predominately binds insulin but also IGF-I and 
IGF-II to a far lesser extent. The IGF-I receptor binds with high affinity to IGF-
I and with 10 fold less affinity to IGF-II and 100 fold less to insulin (Ballard et 
al., 1988; Florini et al., 1996). The IGF-II receptor binds IGF-II with high 
affinity and can also bind IGF-I to a much lesser extent. The most commonly 
accepted function of the IGF-II receptor is that of a sink for excess IGF-II, 
although it may transduce some of the IGF-II signal within the cell (Kornfeld, 
1992; Florini et al., 1996). 
 
Overexpression of a dominant negative IGF-I receptor in mice results in 
reductions in the size of muscles at birth to 5 weeks of age. This reduction 
occurs due to a delay in myogenic proliferation and differentiation. However, 
compensatory hyperplasia occurs by eight weeks of age to recover most of the 
lacking muscle. Mice devoid of IGF-I receptor expression have severe muscle 
hypoplasia resulting in death at birth due to respiratory failure (Liu et al., 1993). 
In contrast, mice lacking the IGF-II receptor have elevated IGF-II serum levels 
and an increased growth rate. These mice are 135% the normal body weight at 
birth but usually die perinatally. Mutants lacking both the IGF-I and the IGF-II 
receptors show a rescue of this phenotype, indicating that IGF-II signals mainly 
through the IGF-I receptor with the IGF-II receptor removing excess IGF-II 
from serum (Ludwig et al., 1996). 
 
IGF-I and IGF-II have been shown to be critically involved in skeletal muscle 
development (Florini et al., 1991a) and in adult muscle regeneration and 
hypertrophy through satellite cell activation and differentiation (Rosenblatt et 
al., 1994; Barton-Davis et al., 1999). In cell culture studies, differentiating 
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C2C12 cells have been shown to express significantly higher levels of IGF-II 
than IGF-I (Tollefsen et al., 1989). IGF-II has been shown to be essential for the 
differentiation of satellite cells through the ability of IGF-II antisense 
oligonucleotides to block differentiation (Florini et al., 1991b). 
 
Scatter factor/hepatocyte growth factor (SF/HGF) is involved in the disruption 
of cell-cell contacts and cell migration in vitro (Matsumoto et al., 1994). 
SF/HGF has an important role in the recruitment and migration of muscle 
precursor cells from the dermomyotome to the limb buds, including maintaining 
the cells’ undifferentiated state, enhancing cell motility, and influencing the 
direction of muscle precursor migration (Scaal et al., 1999). SF/HGF functions 
by activating the c-met transmembrane tyrosine kinase through phosphorylation 
(Ludwig et al., 1996). In mice lacking either SF/HGF or the c-met receptor, no 
muscle precursor cells enter the limb buds and no musculature forms in the limb 
buds, distal tongue, or the diaphragm (Brand-Saberi et al., 1989; Bladt et al., 
1995). 
 
The transforming growth factor beta superfamily (TGF-β) consists of more than 
thirty different members which share several common structural features. These 
common features include: a hydrophobic core of amino acids in the N-terminal 
region that functions as a secretory signal; a RSRR proteolytic processing signal 
in the C-terminal region; nine cysteine residues in the C-terminal portion that 
facilitate the formation of a ‘cysteine knot’ structure after cleavage at the 
processing site (McPherron & Lee, 1996). TGF-β family members have a 
variety of effects during development as well as in regulating tissue function 
during adult life. The growth and differentiation factor (GDF) family is a 
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subgroup of the TGF-β superfamily. GDF8, also known as myostatin, has been 
shown to negatively regulate muscle mass, with dramatic increases in muscle 
seen through non-functional myostatin mutations. More detail on myostatin is 
given in the following section. 
 
1.3 Myostatin 
Myostatin is a Transforming Growth Factor-beta (TGF-β) family member that 
negatively regulates skeletal muscle growth (Fig 1.4). When myostatin is 
disrupted in mice, muscle mass increases up to three-fold due to both muscle 
cell hyperplasia and hypertrophy (McPherron et al., 1997). Natural myostatin 
mutations are present in heavily muscled Belgian Blue, Piedmontese, and 
Asturiana de los Valles cattle breeds (Kocamis et al., 2002). Although there are 
different myostatin gene mutations present in these breeds, they have the same 
condition of muscular hypertrophy primarily resulting from hyperplasia relative 
to normal cattle (Kambadur et al., 1997; Grobet et al., 1998). A myostatin 
mutation has also been detected in a young male human. This individual’s 
quadricep muscle has a cross-sectional area of over two-fold larger than control 
subjects of the same age and gender. Significantly smaller subcutaneous fat 
pads are also seen compared to control subjects. This particular myostatin 
mutation was identified as a G to A transition within the non-coding region of 
the first intron. In cultured muscle and non-muscle cells, this mutation results in 
a splicing error of the precursor mRNA to include the first 108 bp of the first 
intron (Schuelke et al., 2004). 
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Figure 1.4  Myostatin mutations in mice, humans and cattle 
A, Wild-type mouse forelimb; B, Myostatin-null mouse forelimb (Adapted from 
McPherron et al., 1997); C, Myostatin-null human boy, aged 7 months (Adapted 
from Schuelke et al., 2004); D, Myostatin-null Belgian Blue bull (Image from 
the Haliba Genetics Artificial Insemination Centre of Belgium catalogue, 1996). 
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The expression of myostatin is predominately in skeletal muscle but low-level 
expression is seen in the heart (Sharma et al., 1999), mammary glands (Ji et al., 
1998), and brain (Ostbye et al., 2001). Myostatin expression is detected in 
embryonic, foetal, and postnatal myogenic cells. It is initially detected in the 
developing murine somites at 9.5 days post-coitum (d.p.c.) and is detected in a 
wide range of developing muscles in later stages of embryogenesis (McPherron 
et al., 1997). Myostatin expression continues throughout myogenesis and is 
detected postnatally in various axial and paraxial muscles (McPherron et al., 
1997; Jeanplong et al., 2001). In cell culture studies, myostatin has been shown 
to inhibit the progression of myoblasts at the G1 and G2 phases of the cell 
cycle. This cell cycle arrest occurs through the up-regulation of p21, and down-
regulation of cyclin-dependent-kinase-2 (Cdk2) resulting in inhibition of 
progression into the S phase of the cell cycle by hypophosphorylation of 
Retinoblastoma protein (Rb) (Thomas et al., 2000). Along with myoblast 
proliferation, myostatin has also been shown to be an inhibitor of myoblast 
differentiation. This inhibition appears to be through the induction of Smad3 
phosphorylation and increased Smad3·MyoD association, therefore interfering 
with MyoD activity and expression (Langley et al., 2002). Along with muscle 
formation and growth, myostatin is also associated with the loss of skeletal 
muscle mass and increased myostatin levels have been shown in various muscle 
wasting conditions (Artaza et al., 2002), and appears to have a role in muscle 
regeneration (Kirk et al., 2000). 
 
1.3.1 Myostatin structure and synthesis 
The myostatin gene maps to chromosome 2 in humans (McPherron et al., 
1997), and to chromosome 1 in the mouse (Szabo et al., 1998). The myostatin 
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protein is encoded by a 7.8 kb gene which consists of three exons with two 
intervening introns. The myostatin gene is processed to an approximately 3.1 kb 
mRNA transcript, and in humans, results in the translation of a 375 amino acid 
protein (Gonzalez-Cadavid, 1998). The mouse myostatin amino acid sequence 
has 90% identity over the entire protein when aligned to the human sequence, 
and homology increases to 100% when the mature proteins are compared 
(McPherron et al., 1997). The predicted structure of the myostatin protein 
displays classic features of the TGF-β family of signalling proteins. These 
common features include: a hydrophobic core of amino acids in the N-terminal 
region that functions as a secretory signal; a RSRR proteolytic processing signal 
in the C-terminal region; and nine cysteine residues in the C-terminal portion 
that facilitate the formation of a ‘cysteine knot’ structure (Sharma et al., 1999). 
 
The proteolytic cleavage of the 375 amino acid myostatin precursor occurs at 
the RSRR (263-266) site. The resulting myostatin propepetide consists of a 
small N-terminal signal sequence followed by a 28 kDa region known as the 
latency associated protein or LAP-fragment, and a 12 kDa ‘mature’ region at 
the C-terminus (McPherron et al., 1997). The N-terminal signal sequence is 
required for processing and secretion, whereas the LAP-fragment regulates the 
biological activity of myostatin. 
 
Myostatin protein can be present in an active or an inactive (latent) form, which 
is dependent on a series of post-translational modifications (McPherron et al., 
1997; Thies et al., 2001; Hill et al., 2002). These post-translational 
modifications consist of three main processes: first, disulphide bonds are 
formed in regions of myostatin forming a homodimeric protein: second, specific 
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proteolytic cleavage of myostatin occurs to form a propeptide and mature 
region: third, non-covalent forces between the propeptide and mature region 
forms a stable protein complex (Zimmers, 2002). 
 
Myostatin is also differentially processed between male and female mice. 
Although no change is seen in myostatin mRNA, the expression of the 28 kDa 
processed LAP-fragment is 40-60% lower in male muscle. This decrease in 
processed myostatin is associated with the increased skeletal muscle mass 
apparent in male compared to female mice (McMahon et al., 2003). 
 
1.3.2 Myostatin function  
The expression of myostatin in skeletal muscle is mainly associated with fast 
type-IIb fibres (Carlson et al., 1999; Kirk et al., 2000). Consequently, double-
muscled cattle have been found to have an increase in number and size of fast-
type/white fibres and myostatin-null mice have an increase in the proportion of 
fast type-II/glycolytic fibres (West, 1974; Girgenrath et al., 2005). In mice, this 
fibre-type-specific expression of myostatin has been shown to be driven by 
sequences within the 2.5 kb region of the murine myostatin promoter (Salerno 
et al., 2004).  
 
Myostatin also appears to be involved in muscle regeneration after injury.  Kirk 
et al. (2000) found high levels of myostatin in necrotic fibres and connective 
tissue during the early stages after notexin injury. After this initial damage 
phase, a reduction in myostatin protein was observed along with new fibre 
synthesis. Myostatin expression was shown to be differentially expressed 
between fibres that survived injury and regenerating fibres. Kirk et al. (2000) 
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believed that myostatin may act as a chemoattractant in damaged muscle for 
phagocytes and inflammatory cells, or as an inhibitor of their proliferation. 
Muscle wasting conditions where increased myostatin levels have been shown 
in serum and skeletal muscle include severe HIV infection (Gonzalez-Cadavid 
et al., 1998), prolonged bed rest (Zachwieja et al., 1999), old age, and micro-
gravity conditions during space flight (Lalani et al., 2000). 
 
Various studies have shown myostatin to inhibit the differentiation of myoblasts 
in a dose-dependant manner (Langley et al., 2002; Rios et al., 2002; Joulia et 
al., 2003). In addition, Langley et al. (2002) showed this inhibition by myostatin 
to be reversible. Excess myostatin during differentiation inhibits the mRNA and 
protein levels of MyoD, myogenin, p21, and MHC, and inhibited the activity of 
creatine kinase (Langley et al., 2002; Rios et al., 2002). In agreement, Joulia et 
al. (2003) showed that overexpression of myostatin anti-sense upregulated 
MyoD mRNA and p21 protein levels. However, overexpression of MyoD did 
not rescue the myostatin-induced inhibition of myoblast differentiation 
(Langley et al., 2002).  
 
In addition to the regulation of the proliferation and differentiation of myoblasts 
during development, myostatin appears to continue to be involved in postnatal 
muscle growth and repair. The continuing expression of myostatin in adult 
muscle has been detected by various investigators (Kambadur et al., 1997; 
McPherron et al., 1997; Gonzalez-Cadavid et al., 1998; Ji et al., 1998).  
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1.3.3 Myostatin signalling and downstream factors  
Myostatin has been shown to bind to activin receptor type-IIb (ActRIIB) and to 
a lesser extent ActRIIA receptors. The activin type-II (ActRII) receptors are a 
family of serine/threonine kinase transmembrane receptors on target cells. The 
binding of myostatin to ActRII receptors results in the phosphorylation and 
subsequent activation of the activin type-I receptor (Lee et al., 2001). This 
initiates an intracellular signalling cascade through the phosphorylation of the 
receptor-regulated proteins Smad2 and Smad3, which form heterodimers with a 
co-Smad known as Smad4. The activated Smad complex then translocates from 
the cytoplasm to the nucleus where the transcription of target genes can then 
occur (Langley et al., 2002; Shi et al., 2003).  
 
Lee and McPerron (2001) demonstrated that the heavy muscled phenotype 
could be seen through the inhibition of myostatin and ActRIIB. This was 
achieved with transgenic mice expressing high levels of the myostatin 
propeptide, the activin-binding protein follistatin, or a dominant negative form 
of ActRIIB using a muscle specific promoter. Dramatic increases in muscle 
mass were seen in independent transgenic mouse lines for each construct, 
suggesting the potential of molecules that block signalling through this pathway 
for enhancing muscle growth. 
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1.4 Mighty 
1.4.1 Discovery of mighty 
To further understand downstream signalling of myostatin, a genetic screen was 
performed on the skeletal muscle of myostatin-null and wild-type mice. It was 
found that heavily muscled mice, lacking myostatin, had increased mRNA 
expression of a novel gene with no previously characterised function. This 
novel gene was found to be conserved, with cognates found in mammals, 
amphibians, teleosts, and arthropods. The novel gene, later named mighty, was 
found to be expressed in a variety of tissues. Mighty mRNA expression is 
upregulated in myostatin-null m. biceps femoris, m. tibialis anterior, m. 
gastrocnemius, m. quadriceps femoris, m. masseter, and the diaphragm. This 
upregulation varies between different muscles which may be due to differences 
in myostatin expression. Other tissues shown to express mighty mRNA include 
the liver, kidney, heart, testes, and brain, suggesting a ubiquitous role. 
However, these tissues do not show increased mighty mRNA expression in 
myostatin null mice, indicating the specific regulation of mighty by myostatin 
in skeletal muscle (Marshall, 2005). 
 
1.4.2     Mighty overexpressing myoblasts 
With mighty gain-of-function C2C12 myoblast clones, cells show significant 
hypertrophy of both myoblasts and myotubes. These cells dramatically 
overexpress IGF-II and have increased levels of phospho-Akt in actively 
growing and differentiating conditions. Enhanced differentiation of mighty 
overexpressing myoblasts is also observed. This enhanced differentiation 
involves earlier formation of multinucleated myotubes and increased and earlier 
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expression of myogenic differentiation markers MyoD, p21, myogenin, and 
MHC. 
 
1.4.3      Mighty and myostatin 
Dose-dependent inhibition of mighty promoter expression was seen with 
increasing concentrations of myostatin, indicating myostatin regulation of gene 
expression from the mighty promoter. This inhibition was not rescued by the 
protein synthesis inhibitor cycloheximide, showing that myostatin regulation of 
the mighty gene is not mediated through denovo protein synthesis (Marshall, 
2005). Myostatin’s previously characterised signalling pathway through 
ActRIIB, ALK5, Smad2, and Smad3 (Lee and McPherron, 2001; Langely et al., 
2002; Rebbapragada et al., 2003; Zhu et al., 2004) was shown to also regulate 
mighty expression (Marshall, 2005). This was shown by using either dominant 
negative (dn) ActRIIB, ALK5, Smad2, or Smad3 cotransfected with the mighty 
1.1 kb promoter. All these dn-constructs rescued the levels of mighty promoter 
expression in the presence of myostatin. Myostatin may also signal the mighty 
gene via the MEK MAPK pathway, as shown by the rescue of myostatin 
inhibition of the mighty promoter in the presence of the MEK inhibitor, 
PD98059. 
 
The mighty 1.1 kb promoter (+129 through -960) contains five MRF binding 
sites (E-boxes) which were identified using TFSEARCH to be consensus 
binding sites specific for MyoD. In agreement, cotransfection experiments with 
the mighty promoter showed a 2.5-fold upregulation of mighty promoter 
activity with MyoD cotransfection, whereas no significant increase was seen 
with Myf5 or myogenin. Therefore, the upregulation of mighty mRNA 
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expression during myogenic differentiation may be due to MyoD increasing 
mighty promoter activity (Marshall, 2005). 
 
The mighty 1.1 kb promoter also contains ten GATA sites. In previous studies, 
GATA2 has been shown to play a role in skeletal muscle hypertrophy (Musaro 
et al., 1999; Sakuma et al., 2003; De Arcangelis et al., 2005). Cotransfection of 
GATA1, -2, and -3 expression constructs with the mighty 1.1 kb promoter 
showed a positive effect (1.4-1.7 fold induction) on mighty promoter expression 
in C2C12 myoblasts. This indicates that hypertrophic stimuli, leading to 
GATA2 expression, could result in upregulation of mighty gene expression. 
 
1.4.4 Characteristics of the mighty protein 
The predicted ORF for mighty from mouse cDNA (Genbank accession number 
BC003291) is 576 bp long and codes for a 191 amino acid protein. The mouse 
mighty protein was predicted to have a molecular weight of 21676 Da and a pI 
of 8.91. Homology searches showed the mouse mighty protein to have 98% 
sequence homology with the rat and 93% homology with human mighty. 
Homology was lower with non-mammalian species; 37% for Drosophilia 
melanogaster and 27% for Caenorhabitis elegans, although N-terminal and C-
terminal sequences share greater homology (Marshall, 2005). The function of 
the mighty-like protein in Caenorhabitis elegans has been briefly investigated 
using RNA interference (RNAi). This knockdown by RNAi resulted in 
embryonic lethality in Caenorhabitis elegans, indicating a vital role for mighty 
(Maeda et al., 2001). 
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The mouse mighty protein was predicted to be nuclear-localised with a 
reliability of 94.1% using the Reinhardt’s method (Reinhardt & Hubbard, 1998) 
for cytoplasmic/nuclear discrimination (Marshall, 2005). In agreement, 
immunolocalisation studies show that endogenous mighty protein localises to 
the nucleus and the ER. Several possible phosphorylation sites within the 
mighty protein sequence were detected using PROSITE. These included five 
potential protein kinase C (PKC) phosphorylation sites and one potential 
protein kinase CK2 (CK2) phosphorylation site. The PKC sites are at amino 
acids 6-8 (TLK), 22-24 (SPK), 65-67 (SER), 132-134 (TLR), and 160-162 
(STK) and were predicted from the consensus sequence S/T-X-R/K where the S 
or T is the phosphorylation site (PROSITE: PS00005). The CK2 site was 
predicted at amino acids 97-100 (SqsE) and was predicted according to the 
consensus sequence (S/T)-X-X-(D/E) where S or T is the phosphorylation site. 
Two potential myristoylation sites were also predicted at amino acids 117-122 
(GSpgAF) and 183-188 (GTprTS) (PROSITE: PDOC00008). However, for 
myristoylation to occur the glycine residue must be made N-terminal by protein 
cleavage (Marshall, 2005). 
 
The secondary structure of the mighty protein was predicted using the 
Biomolecular Engineering Research Centre (BMERC) protein structure 
prediction program. This data estimates three α-helices from amino acid 
residues 12-18, 74-102, and 138-180 with predominately loop structures for the 
remainder of the protein. The tertiary structure is more difficult to predict as the 
mighty protein sequence does not share a large degree of homology with any 
protein sequence of known function. The BLOCKS database showed the 
mighty protein may contain a forkhead transcription-factor domain from amino 
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acids 49-89. Although the mighty protein shows poor homology with known 
forkhead domains listed on NCBI, there is large variation within the forkhead 
domains of known forkhead transcription factors. In addition, the secondary 
structure of mighty was predicted to be similar to the forkhead domain seen in 
the DNA binding proteins histone H5, E2F4, and DP2 (Marshall, 2005).  
 
1.5 Aims of this thesis 
The formation of muscle is a complex process involving many genes and 
various signalling pathways. A novel gene mighty is up-regulated in myostatin-
null mice which display extensive muscle growth, therefore mighty appears to 
act downstream of myostatin as a positive regulator of muscle growth. Based on 
sequence and protein domain analysis it appears that mighty is a myogenic 
factor involved in early myogenesis by having a role in the 
determination/proliferation and/or differentiation stages of skeletal myoblasts.  
 
This study aimed to characterise the endogenous mighty protein and determine 
its role during myogenesis. This study had three main objectives to achieve its 
aim:  to characterise the mighty protein; to determine if mighty is differentially 
expressed during the cell-cycle; and to establish the expression profile of 
mighty during myoblast differentiation.  
1. Characterisation of the mighty protein. This involved the use of two 
separate mighty anitibodies to assess mighty expression during over-expression, 
knockdown, in different cell types and tissues, and in nuclear extracts. The 
mighty protein was also to be purified and examined by mass-spectrometry 
analysis. 
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2. Mighty expression during the cell-cycle. This involved synchronising 
myoblasts at various stages of the cell-cycle and determining mighty protein 
expression. 
3. Mighty expression during differentiation. This involved analysis of mighty 
expression during differentiation with C2C12 myoblasts and with normal-
muscle (NM) and double-muscle (DM) bovine primary myoblasts. Also, RNAi 
was used to assess the effect of knocking down mighty expression.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38
CHAPTER TWO 
MATERIALS AND METHODS 
This chapter contains general information on chemicals and reagents. Common 
methods used in this project are described with specific methods or alterations 
described within the individual chapters.  
 
2.1 Materials 
2.1.1 Solutions 
Common solutions and their compositions are listed in Table 2.1. 
Table 2.1  Common Solutions 
Solution Composition 
BSA blocking solution (Western) 0.3 g BSA 
      1 g PVP 
      1 g PEG 
      to 100 mL with TBST 
 
Cell Nuclear Extraction   10 mM hepes 
(Buffer A)    1.5 mM MgCl 
      10 mM KCl 
      1 mM DTT  
      1X protease inhibitor (Complete; Roche) 
 
Cell Nuclear Extraction   20 mM hepes 
(Buffer B)    25 % glycerol 
      420 mM KCl 
      0.2 mM EDTA 
       mM DTT 
      1X protease inhibitor (Complete; Roche) 
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Solution Composition 
IEF Sample Buffer   8.0 M urea 
(IEF-SB)    3.0 M thiourea 
      65 mM DTT   
      65 mM CHAPS 
      few grains of bromophenol blue 
      Milli-Q water  
 
Lysis Buffer (protein extraction) 50 mM Tris (pH 7.5) 
      250 mM NaCl 
      5 mM EDTA 
      0.1% (v/v) NP-40 
      1X protease inhibitor (Complete; Roche) 
 
Milk Blocking Solution (Western) 5% (w/v) solution of low fat milk in 
TBST 
 
Muscle Nuclear Extraction  20 mM hepes-NaOH (pH 7.9) 
(Binding buffer)    2 mM MgCl 
      40 mM KCl 
      10 % glycerol 
      1X protease inhibitor (Complete; Roche) 
 
Muscle Nuclear Extraction  10 mM hepes-NaOH (pH 7.9) 
(Buffer 1)    10 mM MgCl 
      5 mM KCl 
      0.1 mM EDTA 
      0.1% triton X-100 
      1X protease inhibitor (Complete; Roche) 
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Solution Composition 
Muscle Nuclear Extraction  20 mM hepes-NaOH (pH 7.9) 
(Buffer 2)    1.5 mM MgCl 
      500 mM NaCl 
      0.2 mM EDTA 
      25 % glycerol 
      1X protease inhibitor (Complete; Roche) 
 
PBS     1 phosphate buffered saline tablet  
      (Oxoid) 
to 100 ml with Milli-Q water 
 
Protein Sample Buffer   10% glycerol 
(NuPAGE® LDS)   141 mM Tris base 
      106 mM Tris HCl 
      LDS 2% 
      0.51 mM EDTA 
      0.22 mM SERVA® Blue G250 
      0.175 mM phenol red 
      pH 8.5 
 
Rehydration Buffer   8.0 M urea 
      2.0% (w/v) CHAPS 
      6 mM DTT 
      2.0% (w/v) ampholytes, pH 3.5-10.0 
      few crystals of Orange-G 
      Milli-Q water   
 
Resolving Gel Solution    1.5 M Tris (pH 8.8)  62 ml        
(250 ml)     Milli-Q water   83 ml  
30% Stock acrylamide 104 ml 
      10% APS    2 ml 
                                                           TEMED   100 µl 
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Solution Composition 
Stacking Gel Solution   0.5 M Tris (pH 6.8)  15 ml 
(60 ml)     Milli-Q water   36.7 ml 
      30% stock acrylamide  8 ml 
      10% APS   270 µl 
      TEMED   30 µl 
 
Stock acylamide    30% (w/v) acrylamide 
      0.8% (w/v) bis-acrylamide 
      Filter through Whatman No.1  
 
TBST     50 mM Tris (pH 7.5) 
      150 mM NaCl 
      0.1% (v/v) Tween 20 
 
TE     10 mM Tris-Cl (at desired pH) 
      1 mM EDTA (pH 8.0) 
 
Transfer Buffer (Western)  25 mM Tris 
      190 mM glycine 
      20% (v/v) methanol 
 
Trypsin (10X)    2.5% (v/v) trypsin in PBS 
 
Western Running Buffer  50 mM MES pH 7.2 
(NuPAGE® MES SDS)   50 mM Tris base 
      0.1% (v/v) SDS 
      1 mM EDTA 
      pH 7.3 
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2.1.2 Common laboratory chemicals and reagents 
All common laboratory chemicals and reagents are specified in Table 2.2. All 
chemicals and reagents are Analar grade unless otherwise stated. 
 
Table 2.2  Chemicals and Reagents 
Chemical or Reagent  Source 
Ethanol; glycerol; hydrochloric acid;  BDH Ltd 
methanol; sodium chloride; Tween-20;  
EDTA; sodium hydroxide (pelleted);  
isopropanol; glucose 
 
Bradford protein assay   BioRad 
 
Ultra pure agarose; ethidium bromide;  Invitrogen (Gibco BRL) 
formamide; sodium dodecyl sulphate 
(SDS); Tris; SeeBlue® Plus2 prestained  
protein ladder; glycine; NuPAGE 4-12% 
Bis-Tris precast protein gels; DMEM  
(dulbeccos modified eagle medium); 
 
Kodac imaging film (X-OMAT AR) Radiographic Supplies 
 
βMe (Beta-mercaptoethanol)   Sigma-Aldrich   
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2.1.3 Antibodies 
Antibodies used in this thesis and their sources are listed in Table 2.3. 
 
Table 2.3  Primary antibodies 
Antibody Source 
Mouse anti-GAPDH   Research Diagnostics Incorporated  
Mouse anti-p21    BD Biosciences Pharmingen 
Mouse anti-tubulin   Sigma 
Rabbit anti-cyclinA   Santa Cruz Biotechnology, Inc 
Rabbit anti-MHC (MF-20)  DSHB, University of Iowa 
Rabbit anti-mighty (bovine)  AgResearch 
Rabbit anti-mighty (peptide)  QED Biosciences  
Rabbit anti-Myf-5   Santa Cruz Biotechnology, Inc 
Rabbit anti-MyoD   Santa Cruz Biotechnology, Inc 
Rabbit anti-myogenin   Santa Cruz Biotechnology, Inc 
Rabbit anti-SP1    Abcam 
 
 
2.1.4 C2C12 mouse myoblasts 
Immortalised C2C12 mouse myoblasts were obtained from the American Type 
Culture Collection (ATCC) (Yaffe and Saxel, 1977). C2C12 cells express 
myogenic regulatory factors important in myogenisis and cell cycle regulation. 
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2.2 METHODS 
Experiments were all performed with Milli-Q purified water (17.5 MΩ) at room 
temperature unless otherwise stated. All cell culture work was carried out in 
laminar flow hoods in a tissue culture suit. Commonly used methods are listed 
below, whilst methods specific to a particular chapter are listed in the 
appropriate section.  
 
2.2.1 Murine muscle removal 
4 week old mice were killed by asphyxiation with CO2 and cervical dislocation 
as required by the Ruakura Small Animal Colony (SAC). Ethics approval was 
granted from both AgResearch and The University of Waikato. The murine hind 
limb muscle were removed and either placed in PBS or immediately frozen in 
liquid nitrogen.  
 
2.2.2 Myoblast cell culture 
2.2.2.1 Isolation of murine primary myoblasts 
Hind limb muscles were removed from 4-week old mice, minced thoroughly 
and digested with 0.2% collagenase 1A in DMEM (no serum) at 37oC with 
shaking (70 rpm) for 90 min.  The digest was triturated with a 10 ml pipette 
repeatedly until no lumps were visible.  The suspension was then filtered 
through a 100 µm and then a 70 µm filter.  The filtered suspension was 
centrifuged at 4,000 rpm for 10 min and the pellet resuspended in 8 ml of warm 
satellite cell proliferation medium [DMEM, 20% foetal bovine serum (FBS), 
10% horse serum (HS), 1% chick embryo extract (CEE)].  The cell suspension 
was pre-plated on uncoated 10 cm plates for 1.5 h, then transferred to 10% 
matrigel plates and incubated for 48 h at 37°C.  After 48 h the media was 
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changed to proliferation media [DMEM + 10% FBS].  After approximately 24 h 
in actively growing conditions the cells were treated depending on the specific 
experiment undertaken.  
 
2.2.2.2 Isolation of primary bovine myoblasts 
Bovine normal muscle (NM) and double muscle (DM) myoblasts were isolated 
by Mark Thomas at AgResearch (Ruakura) from day 90 foetal bovine muscle. 
 
2.2.2.3 Media components and the culturing of C2C12 myoblasts 
C2C12 myoblasts were cultured in Proliferation Medium which contained 
Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen), 10% FBS 
(Invitrogen), 7.22 nM phenol red (Sigma), 1 x 105 IU/L penicillin (Sigma), 100 
mg/l streptomycin (Sigma). The medium was buffered with 41.9 mM NaHCO3 
(Sigma) and gaseous CO2. All medium components were filter-sterilised with 
0.22 µm pore filters. C2C12 myoblasts were cultured in incubators at 37oC, in 
5% CO2 at specific experimental conditions.  
 
2.2.2.4 Trypsinisation of  cultured myoblasts from 10 cm plates 
The harvesting of myoblasts was achieved by the removal of the medium, 
followed by two washes with 5 ml of phosphate buffered saline (PBS). 5 ml of 
1X trypsin (Invitrogen) was added to each plate and left at RT for 30 s. About 4 
ml was removed and the cells were incubated at 37oC until the cells had 
detached (~ 10 min). Cells were washed off the plate with 5 ml of Proliferation 
Medium and transferred to a centrifuge tube. The cells were pelleted at 4,000 G 
and washed in 5 ml of PBS. The cells were then pelleted again at 4,000 G, the 
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supernatant removed, and the cells resuspended in 100-200 µl of lysis buffer. 
The cells were stored at -80oC until protein extraction. 
 
2.2.2.5 Scraping of cultured myoblasts from 6-well plates 
Cultured myoblasts grown on 6-well plates had their medium removed and were 
then washed twice with 5 ml of PBS per well. 100-200 µl of Lysis Buffer was 
added to each well and the cells scraped with the blunt end of a 1 ml pipette tip. 
After approximately 1 min of scraping per well, the liquid was transferred to a 
1.5 ml Eppendorf tube and frozen at -80oC until protein extraction. 
 
2.2.2.6 Protein extraction from cultured myoblasts 
Total protein was extracted from cultured myoblasts for analysis by Western 
Blotting. After harvesting of the cells, the cell lysate was passed through a 0.45 
mm gauge syringe needle 10 times. The cell lysate was then centrifuged at 
12,000 G for 10 min with the supernatant removed and the resulting protein 
solution stored at -80°C. 
 
2.2.3 Protein estimation 
2.2.3.1 Bradford assay 
The Bradford Assay (Bradford, 1976) was used to estimate the total protein 
concentration in protein extract samples. Sample protein was added to PBS to 
give a final volume of 100 µl. Bradford Reagent concentrate (BioRad) was 
diluted 1:5 with Milli-Q water and 1.2 ml was added to the diluted protein 
sample. Samples were then mixed and the absorbance measured at 595 nm using 
a UV spectrophotometer (Thermo Spectronic). The absorbances of BSA 
standards (0, 5, 10, 15, 20 µg/ml) were measured to generate a standard curve 
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with which the unknown sample protein was compared and the protein 
concentration estimated. 
 
2.2.3.2 2-D protein quantitation 
The 2-D Quant Kit (Amersham Biosciences) is designed for the accurate 
quantitation of protein concentration in samples for high resolution 
electrophoretic techniques such as 2-D electrophoresis. The procedure 
quantitatively precipitates proteins while leaving interfering substances in 
solution. The assay is based on the specific binding of copper ions to protein and 
the colour density is inversely related to the protein concentration. The assay has 
a linear response to protein in the range of 0-50 µg. 500 µl of precipitant was 
added to each tube, vortexed briefly and incubated for 2-3 min at RT. 500 µl of 
co-precipitant was then added to each tube and mixed briefly by vortexing. The 
tubes were then centrifuged at 15,000 G for 5 min to pellet the protein. The 
supernatant was then decanted and the tubes briefly centrifuged again, the 
remaining liquid was then removed using a micropipette. 100 µl of copper 
solution and 400 µl of Milli-Q water were then added to each tube and vortexed 
briefly. 1 ml of working colour reagent (100 parts colour reagent A with 1 part 
colour reagent B) was added to each tube and mixed by inversion. The samples 
were then incubated at room temperature for 15-20 min before reading the 
absorbance at 480 nm. The unknown samples were compared with BSA 
standards (0, 10, 20, 30, 40, 50 µg) to determine the protein concentration of the 
samples.  
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2.2.4 SDS polyacrylamide gel electrophoresis 
Separation of protein for Western blotting was achieved using NuPage 4-12% 
gradient Bis-Tris pre-cast polyacrylamide gels (Invitrogen) in the XCELL II 
Mini gel apparatus (Novex) with 1X Nupage MES SDS running buffer 
(Invitrogen). Samples were mixed with 4X NuPage Sample Buffer (Invitrogen) 
and β-mercaptoethanol before boiling for 5 min. Samples were run with the 
SeeBlue Plus2 Pre-Stained Standard (Invitrogen) to give a guide to the 
molecular weights of the proteins in the gel. 
 
2.2.5 Western blotting 
Following electrophoresis, the acrylamide gels were removed from their pre-cast 
casing and washed in Western Blot Transfer Buffer. The protein was transferred 
to Trans-Blot (Bio-Rad) nitrocellulose membrane by electroblotting using the 
XCell II Blot Module (Invitrogen). The membranes were then stained with 
Ponceau S. solution for 5 min. Excess stain was washed off with Milli-Q water 
and the blot scanned to show effective transfer of protein. After washing the 
membranes for 5 min in TBST, the membranes were blocked in the appropriate 
blocker. Once blocking was complete, the membranes were incubated with the 
specified 1o antibody and the Horseradish Peroxidase (HRP) conjugated 2o 
antibody. Specific details on blockers, antibodies, and the detection of specific 
proteins is described in the appropriate experimental section. Western Lightning 
Chemiluminescence Reagent (PerkinElmer) was used to produce the 
luminescence reaction. Chemiluminescence was visualised using BioMax XAR 
film (Kodak). The bands were subsequently analysed by densitometry with a 
GS-800 Calibrated Densitometer (BioRad). 
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2.2.6 Statistics 
Power studies are used by AgResearch statisticians to use the minimum number 
of animals while obtaining statistically valid results. Power is a property of a 
statistical significance test which needs to be approved by a statistician for 
AgResearch ethics approval. Results were analysed and the significance of the 
results determined by Student’s t-test. The aim is to achieve at least 80% power 
with a level of significance of 0.05. For each variable, analysis of variance 
(SEM) will be used to determine the statistical significance. Quantitation was 
generally performed by densitometry analysis using a GS-800 Calibrated 
Densitometer (BioRad).  Data were transformed if necessary. 
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CHAPTER THREE 
CHARACTERISATION OF THE MIGHTY PROTEIN 
3.1 Introduction 
To fully understand the role of a particular protein, knowledge about its 
individual characteristics is required. In comparison to DNA, the study of 
proteins can be extremely challenging. While the genome of the cell is constant 
and nearly identical for all cells of an organism, the proteome is very complex 
and dynamic as it responds to various external factors. Proteins are also time- 
and cell-specific and can include isoforms and post-translationally modified 
(PTM) forms. Over 100 different PTMs have been identified so far which can 
dramatically alter the characteristics of a particular protein (O’Donovan et al., 
2001). In addition, the dynamic range of protein expression within the proteome 
can vary by as much as 7-12 orders of magnitude (Pandey & Mann, 2000).  
 
Most of the previous work on characterising the mighty protein has involved the 
hypothetical characteristics established from sequence data. The hypothetical 
mouse mighty protein resulting from the predicted ORF (Genbank accession 
number BC003291) is 191 amino acids long with a predicted molecular weight 
of 21675 Da and pI of 8.91. The mouse mighty protein was predicted to be 
nuclear localised with a reliability of 94.1% using the Reinhardt’s method for 
cytoplasmic/nuclear discrimination (Reinhardt and Hubbard, 1998). Six possible 
phosphorylation sites within the mighty protein sequence were detected using 
PROSITE. Two potential myristoylation sites were also predicted. The 
BLOCKS database showed the mighty protein may contain a forkhead 
transcription-factor domain. In addition, the secondary structure of mighty was 
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predicted to be similar to the forkhead domain seen in the DNA binding proteins 
Histone H5, E2F4, and DP2. Experimental work on recombinant mighty protein 
has shown that mighty does appear to be nuclear localised by both Western 
blotting and ICC using V5 and GFP antibodies (Marshall, 2005).  
 
Most of the work in this chapter will focus on characterising the endogenous 
mighty protein through the use of mighty antibodies. Two mighty antibodies 
will be used; one raised against the full-length bovine recombinant protein and 
the other raised against a conserved synthetic peptide of the mighty protein. 
Western blotting for endogenous mighty protein from various sources will then 
be established using these antibodies along with mighty overexpression and 
knockdown to ensure correct protein identification. Nuclear enrichment will be 
used to identify the localisation of endogenous mighty. The approximate 
isoelectric point of mighty will be established using the Rotofor (BioRad) 
system, which will also be a purification step for two-dimensional gel 
electrophoresis (2-DE). Various purification methods will be trialled, such as 
immunoprecipitation, to prepare mighty for mass-spectrometry analysis (MS).  
 
Various MS systems are available, however, experiments in this chapter will use 
“matrix-assisted laser desorption ionization time of flight” (MALDI-ToF) and 
“electrospray-ionization liquid chromatography tandem mass spectrometry” 
(ESI LC-MS/MS). Mass spectrometry analysis allows for protein identification 
and possible identification of splice variants, isoforms, and PTMs. Purified 
protein samples will be digested by trypsin to produce specific peptides which 
are more soluble and give more precise results for mass detection. The detected 
peptide masses are compared to the theoretical masses of peptides obtained by 
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the in silico digest of the entire protein database. This method is known as 
peptide mass fingerprinting (PMF) and, depending on the matches obtained, can 
enable protein identification. Analysis of these peptides by tandem MS enables 
the amino acid composition and the sequence to be determined. This not only 
gives more rigourous protein identification but also can potentially give the sites 
of post-translational modifications as well as previously unrecognised splice 
variants and protein isoforms (Neverova & Eyk, 2005). 
 
This chapter aims to identify various characteristics of endogenous mighty 
protein which can potentially give clues to the role of mighty in myogenesis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53
3.2 Materials and Methods 
3.2.1 Recombinant mighty proteins 
The recombinant murine (mMty) and bovine (bMty) protein were generated and 
purified by Amy Marshall at AgResearch. pRSETA vector (Invitrogen) was 
digested with BamH1 and Kpn1 and purified. The 655 bp BamH1/Kpn1 
fragment of the IMAGE: clone 3498569 (Resgene) containing the murine ORF 
for mighty was cloned into the pRSETA vector in-frame with the N-terminal 
His tag. The bovine mighty ORF sequence was cloned into Pvu11 and BamH1 
digested pRSETB (Invitrogen). The ligated constructs were transformed into 
DH5α cells and the recombinants analysed by restriction digests to verify 
correct insertion and orientation. The constructs were then transformed into 
BL21 cells and grown to sufficient density. The mMty and bMty recombinant 
proteins were purified using Ni-NTA Agarose resin chromatography (Qiagen). 
 
3.2.2 Antibody purification 
3.2.2.1 Antibodies to full-length bovine mighty; Mighty (bovine) antibody 
The rabbit inoculation and blood collection was performed by the Ruakura 
Small Animal Colony. Blood from a rabbit inoculated with full-length bMty 
protein was spun at 2,000 rpm for 15 min at 4oC. The serum was separated from 
the clot and pH adjusted with 1/10th volume of 1.0 M Tris (pH 8.0). 2.5 ml of 
Protein-A agarose beads were added to an affinity chromatography column. The 
column was then washed with 10 bed volumes (25 ml) of 100 mM Tris (pH 8.0). 
The serum solution was passed through the column (5.5 ml), and the recovered 
solution passed through the column again. Beads were washed with 10 column 
volumes (25 ml) of 100 mM Tris (pH 8.0). A second wash was performed using 
10 column volumes (25 ml) of 10 mM Tris (pH 8.0). The antibodies were then 
 54
eluted from the beads using 500 µl of 100 mM glycine (pH 3.0). The eluate was 
collected in tubes containing 50 µl of 1 M Tris (pH 8.0). The tubes were then 
mixed gently to bring the pH back to neutral. The immunoglobulin-containing 
fractions were identified using the Bradford method for protein estimation 
(Bradford, 1976). 
 
3.2.2.2 Antibodies to a  C-terminal peptide of mighty; Mighty (peptide) antibody 
These antibodies were produced by QED Bioscience Inc by inoculating rabbits 
with a synthetic peptide corresponding with the 18 amino acid C-terminal region 
of the mighty protein. The serum was collected and the specific antibodies 
purified by affinity chromatography using the mighty peptide ligand attached to 
agarose beads. 
 
3.2.3 Myoblast cell culture 
3.2.3.1 Transfection of C2C12 myoblasts  with pcDNA3-Mighty 
C2C12 myoblasts were plated on four 10 cm plates and the cells grown until 
approximately 60% confluent. Per plate, 12.4 µg of pcDNA3-Mighty was 
diluted in 0.8 ml DMEM (no serum) and 12.4 µg of pcDNA3 (control) was 
diluted in 0.8 ml DMEM (no serum). 40 µl of Lipofectamine 2000 (Invitrogen) 
was diluted in 0.8 ml DMEM (no serum) per plate. The diluted DNA and diluted 
Lipofectamine was then combined and incubated for 20 min at RT. 3.6 ml of 
media was removed from each plate, leaving approximately 2.4 ml of media. 1.6 
ml of the appropriate DNA/Lipofectamine solution was then added to each plate 
dropwise with gentle mixing. After 24 h from transfection, the plates were 
removed from the incubator and the protein extracted as in Section 2.2.2.6. 
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3.2.3.2    Transfection of C2C12 myoblasts with Mighty-siRNA 
Refer to Chapter 5, section 5.2.3. 
 
3.2.4 Preparation of nuclear extracts  
3.2.4.1 Nuclear extraction from muscle tissue 
200 mg of frozen murine-hindlimb muscle (WT and myostatin-null) was placed 
in 1 ml of ice-cold ‘buffer 1’ and homogenised on ice. 100 µl of homogenate 
was put aside for analysis and frozen at -80o C. The remaining homogenate was 
centrifuged at 3,000 G for 5 min at 4oC. The supernatant was collected for the 
cytoplasmic fraction and frozen at -80oC. The pellet was resuspended by 
trituration in 400 µl of ice-cold ‘buffer 2’ and incubated on ice for 30 min. The 
suspension was then centrifuged at 3,000 G for 5 min. 200 µl of the supernatant 
was transferred to an Ultrafree filter unit (Millipore, Bedford, Ma, USA) and 
200 µl of ‘binding buffer’ was added. The unit was centrifuged at 4,500 G for 
30 min at 4oC. The nuclear extract remaining in the top portion of the column 
was frozen at -80oC. The protein content was estimated by the Bradford assay.  
 
3.2.4.2    Nuclear extraction from C2C12 myoblasts 
Five 10 cm plates were grown in Proliferation Medium until approximately 80% 
confluent. Each plate was then washed twice with 5 ml of PBS. 8 ml of 
Differentiation Medium was then added to each plate and the cells incubated for 
20 h. After incubation, the cells were trypsinised as in Section 2.2.2.4 except the 
pellet was resuspended in 400 µl of Buffer A and passed through a 0.45 mm 
gauge needle 10 times. The cells were then centrifuged at 20,000 G for 15 s. The 
supernatant (cytoplasmic extract) was removed and stored at -80oC. The pellet 
was then resuspended in 300 µl of Buffer B and left on ice for 20 min. After 20 
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min, the solution was passed through a 0.45 mm gauge needle 10 times. The 
solution was then centrifuged at 20,000 G for 15 s. The supernatant (nuclear 
extract) was removed and stored at -80oC. 
 
3.2.5 Isoelectric fractionization 
The MicroRotofor cell (BioRad) was used to separate C2C12 nuclear-extract 
protein by isoelectric focusing (IEF) in solution. The ion exchange membranes 
were equilibrated in electrolyte solution overnight prior to use: the anode 
membrane in 0.1 M H3PO4, and the cathode membrane in 0.1 M NaOH. The 
focusing components were then assembled as outlined in the manufacturer’s 
instructions. 833 µl (6 µg/µl) of C2C12 nuclear-extract protein was diluted to 3 
ml in Sample Buffer (IEF-SB) containing 60 µl of ampholytes (Bio-Lyte, pH 3-
10). 2.5 ml of the diluted sample was then loaded into the chamber until all of 
the compartments were filled. 6 ml of 0.1 M H3PO4 was added to the vent hole 
of the anode assembly, and 6 ml of 0.1 M NaOH was added to the vent hole of 
the cathode assembly. The rotofor cell was then run at 20oC at 500 V until the 
mA levels remained consistent (~3.5 h). After focusing, the fractions were 
collected using the harvesting station. The fractions were then transferred into 
eppendorf tubes and frozen at -80oC. 
 
3.2.6 Two-Dimensional polyacrylamide electrophoresis  
60 µl of fraction 5 Rotofor (BioRad) sample was made up to 125 µl with Sample 
Buffer (IEF-SB). The diluted sample was incubated for 1 h at RT with periodic 
vortexing to keep the sample in solution. After 225 µl of Rehydration Buffer 
was added, the sample was vortexed and incubated at room temperature for 1 h. 
The sample was then vortexed and centrifuged at 12,000 G for 10 min to pellet 
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insoluble material. The 350 µl sample was pipetted evenly along a lane in a 
rehydration cassette (Pharmacia Biotech). The plastic cover strip was then 
removed from an immobilised pH gradient (IPG) strip (Pharmacia Biotech, pH 
3.0-10.0) and the excess plastic cut from the basic end. The acidic end was then 
held with tweezers and lowered, gel side down, into the well containing the 
sample. After the lid was sealed on the rehydration tray, the sample was left 
overnight at RT with slow rocking. The isoelectric focusing was performed on 
the Bio-Rad Protean II IEF Cell. The pre-cut electrode wicks were dampened 
with Milli-Q water and excess water removed. The wicks were then placed 
across the electrode wire in the IEF cell lane. 1 ml of parraffin oil was added to 
the lane between the wicks. The fully rehydrated strip was added to the IEF tray 
with the acidic end towards the anode and the gel side down. The strip was then 
covered with 1.7 ml of Shell medicinal oil and the lid placed on the IEF tray. 
The IEF tray was placed in the IEF cell and ran overnight at RT. The 2 DE gels 
were run on a Protean II Multicell (BioRad) with the gels cast using a Protean II 
Multigel casting chamber (BioRad) for a 20 cm x 18 cm x 1.0 mm vertical gel. 
250 ml of Resolving Gel Solution (without TEMED) was degassed under 
vacuum for 10 min. 100 µl of TEMED was then added, gently swirled, and 
pipetted  between the glass plates in the casting chamber. 500 µl of water-
saturated butanol was pipetted over the gel solution and the gel left to 
polymerise overnight. The butanol layer was then removed and washed with 1.5 
M Tris (pH 8.8). Degased Stacking Gel Solution was pipetted above the set 
resolving gel up to an IPG strip width from the top of the plates. The IPG strip 
was then placed between the plates and set in place by overlaying with 0.5% 
(w/v) agarose. After approximately 1 h to set, the gel cassette was assembled in 
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the electrophoresis tank and ran for 25 mA/gel until the dye front reaches the gel 
base. 
 
3.2.7 In-gel tryptic digestion 
The specific mighty spot was cut from the gel and placed into a 0.6 ml 
eppendorf tube. 100 µl of 25 mM ammonium bicarbonate/ 50% acetonitrile was 
added to the gel fragment and placed on a shaker at RT for 30 min, the liquid 
was then spun down and removed. This washing procedure was repeated until 
the gel piece was completely destained. 20 µl of 100% acetonitrile was then 
added to the gel fragment until it turned opaque. The gel fragment was then 
dried thoroughly in a vacuum centrifuge. The dried gel fragment was rehydrated 
with 10 µl of 0.1 µg/µl trypsin for 1 h at 37oC. 25 µl of 25 mM ammonium 
bicarbonate solution was then added and incubated at 37oC overnight. The gel 
was then sonicated for 10 min and the liquid transferred to a new tube and the 
pipette tip retained. 20 µl of 25 mM ammonium bicarbonate solution was then 
added to the gel fragment and placed in the sonicating water bath for 10 min. 
Using the same tip as previously, the solution was transferred to the tube 
containing the other supernatant. 10 µl of acetonitrile and 10 µl of 0.5% TFA 
(trifluoric acid) were then added to the gel fragment and sonicated for 10 min. 
The supernatant was transferred to the other supernatant tube using the 
previously saved pipette tip. 10 µl of acetonitrile was then added to the gel 
fragment, sonicated for 10 min, and the supernatant transferred as before. The 
white gel fragment was then discarded and the supernatant lyophilised in the 
vacuum dryer for 1.5 h. The lyophilised protein was then resuspended in 5% 
(v/v) formic acid/ 50% acetonitrile and stored at -20oC until use. 
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3.2.8   Western blotting 
Total protein (15 µg) was separated by SDS-PAGE (4-12% gradient, pre-cast 
gels, Invitrogen) and transferred to nitrocellulose membrane (Bio-Rad) by 
electroblotting as described in Section 2.2.5. For the antibody incubations for 
mighty (bovine), SP1, tubulin, and GAPDH, the transferred membranes were 
blocked in 5% milk (w/v) in TBST at 4oC overnight. Primary antibody 
incubations were performed for 3 h at RT in 5% milk (w/v) in TBST at the 
following dilutions; mighty (bovine), 1:2000 dilution of a purified rabbit 
polyclonal anti-mighty antibody (AgResearch); SP1, 1:5000 dilution of a 
purified rabbit polyclonal anti-SP1 antibody (ab13370; Abcam); tubulin, 1:5000 
dilution of a purified mouse monoclonal anti-tubulin antibody (T-9026 clone 
DM 1A; Sigma); GAPDH, 1:5000 dilution of a purified mouse monoclonal anti-
rabbit glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (RDI-
TRK5G4-6C5; Research Diagnostics Incorporated). Following the incubation, 
the membranes were washed (5 X 5 min) with TBST. After washing, 
membranes were incubated with secondary antibody (1:2000) for 1 h at RT. 
Either anti-mouse IgG HRP conjugate (PO447; DakoCytomation) or anti-rabbit 
IgG HRP conjugate (PO448; DakoCytomation) was used depending on the 
primary antibody. The membranes were then washed (5 X 5 min) in TBST. HRP 
activity was then detected using Western Lightning (PerkinElmer) Western Blot 
Chemiluminescence Reagent. The antibody incubations with mighty (peptide) 
used a different buffer system. The transferred membranes were blocked in a 
BSA buffer (0.3% BSA, 1% PVP, 1% PEG, TBST) for 3 h at RT to block non-
specific antibody binding. The blots were incubated with rabbit anti-mighty 
antibody (peptide) at 1:5000 dilution in BSA solution at 4°C overnight, with 
gentle shaking. Following the incubation, the membranes were washed (5 X 5 
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min) with TBST. The membranes were then incubated with goat anti-rabbit 
conjugated to Horseradish Peroxidase (HRP) (Amersham) 1:2000 dilution in 
BSA solution for 1 h. Following washing (5 x 5 min in TBST), HRP activity 
was detected with ECL reagent (Western Lightning Chemiluminescense 
Reagent Plus). The bands were subsequently analysed by densitometry with a 
GS-800 Calibrated Densitometer (BioRad). For detection of mighty from 
muscle extracts using mighty (peptide) antibodies, the procedure was altered by 
incubating the secondary antibody in 5% milk solution. 
 
3.2.9   Mass-spectrometry analysis 
Mass-spec analysis was performed by either The University of Waikato 
(MALDI-ToF) or HortResearch (ESI LC-MS/MS). The MALDI-ToF (matrix-
assisted laser desorption ionization time of flight) was used to detect peptide 
masses which were compared to the theoretical masses of peptides obtained by 
the in silico digest of the entire protein database (MASCOT). The ESI LC-
MS/MS (electrospray-ionisation liquid chromatography tandem mass 
spectrometry) is a more sensitive technique which enables the amino acid 
composition and the sequence to be determined. 
 
3.2.10 Protein sequence analysis 
To predict the molecular weight and pI of the mighty protein the protein 
molecular weight prediction tool at http://au.expasy.org/tools/pi_tool.htm was 
used. For the prediction of phosphorylation sites and the predicted pI effect, the 
ProMoST prediction tool at http://proteomics.mcw.edu/promost/index.jsp was 
used. For the prediction of potential sumoylation sites the SUMOplot™ tool at 
http://www.abgent.com/doc/sumoplot was used. 
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3.3 Results 
3.3.1 Identification of endogenous mighty protein in C2C12 myoblasts 
Mighty (bovine) and mighty (peptide) antibodies were used to detect the 
apparent endogenous mighty in C2C12 myoblasts. Recombinant mighty protein 
(bMty and mMty) were used as a comparison. Figure 3.1A shows mighty 
(bovine) antibody detecting recombinant bMty and mMty at approximately their 
expected size. No mighty band was visible in the expected size range (~22 kDa) 
in C2C12 cells but a band was detected at approximately 52 kDa. Figure 3.1B 
shows mighty (peptide) antibody did not appear to detect recombinant bMty but 
did detect recombinant mMty at the expected size. Like mighty (bovine) 
antibody, mighty (peptide) antibody detected protein at approximately 52 kDa in 
C2C12 myoblasts. Mighty overexpression (Figure 3.1C) and mighty knockdown 
(Figure 3.1D) was used to further investigate the apparent 52 kDa endogenous 
mighty to confirm its evident molecular weight. 52 kDa mighty levels were 
increased approximately two-fold (p<0.05) through transient-transfection with 
pcDNA3-Mighty. Conversely, 52 kDa mighty levels were decreased by 
approximately 67% (p<0.005) through transfection with mighty-siRNA. 
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Figure 3.1.  Apparent molecular weight of endogenous mighty 
Western blots detecting recombinant (bMty and mMty) and endogenous mighty 
protein with: A, Mighty (bovine) antibodies; and B, Mighty (peptide) antibodies.  
C, Mighty overexpression in C2C12 myoblasts; D, Mighty knockdown in 
C2C12 myoblasts. Expression of the mighty controls was termed 100 and 
relative expression was plotted. Bars represent the relative mean ± SEM of three 
separate experiments. GAPDH and tubulin protein expression levels are 
provided to show even loadings. Upregulation of mighty by overexpression was 
significant by t-test (*p<0.05). Knockdown of mighty by mighty siRNA was 
also significant by t-test (**p<0.005).  
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3.3.2 Endogenous mighty protein is nuclear localised 
Cell and muscle lysates were nuclear enriched to establish the cellular 
localisation of the mighty protein. Mighty (peptide) antibodies were used for 
mighty protein detection. Figure 3.2A shows 52 kDa mighty to be nuclear 
localised in cell extracts from C2C12 myoblasts. Sp1 was used as a marker of 
the nuclear fraction to show the efficiency of the nuclear enrichment technique. 
Figure 3.2B shows 52 kDa mighty protein to be enriched in the nuclear fraction 
of both normal-muscle (NM) and double-muscle (DM) bovine myoblasts. There 
also appeared to be more 52 kDa mighty present in the DM than the NM cells. 
Figure 3.2C shows protein detected in murine muscle extracts was 
approximately 30 kDa. No protein was detected at 52 kDa. The protein detected 
in the muscle extracts at 30 kDa was also nuclear localised and appeared to be 
more abundant in the myostatin KO fraction.   
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Figure 3.2.  Mighty protein in nuclear enriched fractions 
Western blots of nuclear and cytoplasmic enriched fractions from various 
extracts.   
A, Cell extracts from C2C12 myoblasts; B, Cell extracts from NM and DM 
bovine primary myoblasts; C, Muscle extracts from WT and KO murine muscle. 
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3.3.3 Isoelectric point determination of endogenous mighty protein 
The approximate isoelectric point of endogenous mighty was determined by 
isoelectric focusing of the nuclear enriched fraction from C2C12 cells. Figure 
3.3A shows the Rotofor (BioRad) fractions by Coomassie Blue stain. Figure 
3.3B shows the Western blot of the Rotofor fractions with mighty protein seen 
predominately in fraction 5. Figure 3.3C shows the pH values of the various 
Rotofor fractions. The mighty containing Fraction 5 had a pH value of 5.7.    
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Figure 3.3.  Isoelectric determination of endogenous mighty protein  
A, Coomassie blue stained SDS gel of rotofer fractions; B, Western blot of 
rotofer fractions; C, Bar graph of pH values from rotofer fractions. 
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3.3.4 Two-dimensional electrophoresis of endogenous mighty protein 
Fraction 5 of the previously purified Rotofor fractions (Section 3.3.3) was 
separated by two-dimensional electrophoresis (2DE). Two 2DE gels were run 
under the same conditions simultaneously. One gel was Coomassie Blue stained 
to enable spots to be removed and analysed by mass spectrometry. Figure 3.4A 
shows the entire Ponceau S. stained membrane and the protein present from 
fraction 5. Figure 3.4B shows the Western blot portion of the 2DE transferred 
gel incubated with mighty (peptide) antibody. Protein was only detected in the 
45-66 kDa portion of the membrane. Figure 3.4C shows the same Western blot 
previously incubated with mighty (peptide), re-incubated with mighty (bovine) 
antibody.    
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Figure 3.4.  Two-dimensional electrophoresis of endogenous mighty protein 
A, Ponceau S. stained membrane of fraction 5; B, Western blot of fraction 5 
using mighty (peptide) antibody; C, Western blot of fraction 5 using mighty 
(bovine) antibody. 
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3.3.5 Possible peptide masses determined from sequence data 
The expected peptide masses were first determined by sequence data to enable 
identification and comparisons to be made. Figure 3.5A shows the expected 
murine peptide masses after trypsin digestion and the resulting peptide masses 
after cysteine modification by carbidomethyl (CAM) from sequence data. Figure 
3.5B shows the expected murine amino acid sequence with the possible sites of 
post-translational modifications derived from sequence information. Possible 
post-translational modifications identified are: five potential protein kinase C 
(PKC) phosphorylation sites and one potential protein kinase CK2 (CK2) 
phosphorylation site, two potential myristoylation sites, and three potential 
sumoylation sites. 
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Figure 3.5.  Possible peptide masses determined by sequence data 
A, Expected peptide masses from murine mighty sequence; B, Possible post-
translational modifications of murine mighty protein. 
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3.3.6 Peptide mass determination of mMty and bMty 
Both recombinant mighty proteins (mMty and bMty) were analysed by MALDI-
ToF mass spectrometry to confirm their presence and to determine the expected 
peptides from endogenous mighty. Figure 3.6A shows the peptide coverage 
achieved from mMty by mass spectrometry and gives the total peptides 
determined from the murine mighty sample and shows the intensity of the 
various peaks. MASCOT search parameters were used for recombinant mMty 
protein identification (data not shown). A score of 121.00 was achieved which is 
well above the >69.00 required to achieve p<0.05 significance.  Figure 3.6B 
shows the peptide coverage achieved from bMty by mass spectrometry and 
gives the total peptides determined from the bovine mighty sample and shows 
the intensity of the various peaks. MASCOT search parameters were used for 
recombinant bMty protein identification (data not shown). A score of 136.00 
was achieved which is also well above the >69.00 required to achieve p<0.05 
significance.   
 
 
 
 
 
 
 
 
 
 
 
 75
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76
 
 
 
 
 
Figure 3.6.  Peptide mass determination of mMty and bMty 
A, The mMty sequence coverage and peak intensities using Flex analysis; B, 
The bMty sequence coverage and peak intensities using Flex analysis. 
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3.3.7 Attempt to identify endogenous mighty by mass spectrometry  
Twelve spots identified by Western blotting were cut from the Coomassie 
stained 2DE gel and the subsequent digested peptides examined by MS analysis. 
‘spot A’ (Figure 3.4A) was analysed by LC-MS/MS at HortResearch, the MS 
data identified the protein vimentin in ‘spot A’ (data not shown). The other 
eleven spots were analysed by MALDI-ToF at the University of Waikato. In 
addition, four bands were cut from a Coomassie stained 1DE gel from various 
samples purified by affinity chromatography and analysed by MALDI-ToF at 
the University of Waikato. No significant hits were obtained from any of these 
samples for endogenous mighty (data not shown). 
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3.4 Discussion 
The theoretical molecular weight of the mighty protein, based on sequence data, 
is approximately 22 kDa. However, Western blot data shows the apparent 
molecular weight of endogenous mighty to be approximately 52 kDa (Fig 3.1). 
The recombinant mighty proteins (mMty and bMty), migrated at approximately 
30 kDa, which is expected due to the sequence additions from the pRSETA and 
pRSETB vectors. Mighty (peptide) does not appear to detect recombinant bMty; 
this may be due to a possible blocking of the peptide epitope by surrounding 
amino acids from the pRSETA plasmid. There are various possibilities to 
account for why endogenous mighty is detected at 52 kDa and not the expected 
22 kDa including dimerisation, phosphorylation, and sumoylation. Although 
dimers are expected to denature during Western blotting there are examples of 
dimers that resist strong denaturing conditions in the literature. These include 
dimers of β-amyloid (Galeazzi et al., 1999), tubulin, tekin (Stephens, 1998), and 
pilin (Parge et al., 1990). In addition, endogenous mighty appears to be in the 52 
kDa region during 2DE which is carried out under extremely denaturing 
conditions, making endogenous mighty existing as a dimer unlikely. Sequence 
data of mighty shows a possible six phosphorylation sites. Although a single 
phosphorylation adds only 97.9 Da to the mass of a protein, the negative charge 
due to phosphorylation can have a large influence on the migration of proteins 
by electrophoresis. Changes in protein mobility in SDS gels by phosphorylation 
have been shown previously. Phospholamban (Wegener & Jones, 1984), the 
regulatory subunit of type II cAMP-dependent protein kinase (Hofmann et al., 
1975), glycogen synthase kinase (Ahmad et al., 1982), and the 21-kDa oncogene 
product coded for by the Harvey murine sarcoma virus (Shih et al., 1979) have 
all been reported to exhibit phosphorylation-induced mobility decreases in SDS 
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gels. This effect can result in large mobility differences. Julien & Mushynski 
(1982) reported an increase in the apparent Mr of approximately 25 kDa for 
P200, and examples of 30-40% increases in Mr were given by Kaufmann et al. 
(1984) for various neurofilament proteins. Protein mobility shifts in SDS gels 
from phosphorylation is thought to involve either a decrease in the 
phosphoprotein’s ability to bind SDS, or a direct effect of phosphorylation on 
the tertiary structure (Wegener & Jones, 1984). Similarly, phospholamban and 
β-adrenergic receptor have both been shown to have more than one mobility 
form depending upon the level of phosphorylation (Stadel et al., 1983; Wegener 
& Jones, 1984). Another possible post-translational modification occurring with 
endogenous mighty is sumoylation. SUMO is an abbreviation for ‘small 
ubiquitin-like modifier’ and many known SUMO substrates are transcription 
factors or coregulators of transcription. Sumoylation is the covalent addition of a 
98 amino acid polypeptide to a consensus SUMO-acceptor site. This 
modification has been shown to alter protein mobility in SDS-PAGE, with 
Perdomo et al. (2005) reporting an apparent 24 kDa increase with sumoylated 
BKLF (basic Kruppel-like factor). Mighty contains three potential sumoylation 
sites with the most likely site having a score of 0.94 (SUMOplot™). However, 
the sumoylation/desumoylation cycle appears to be highly dynamic, with only a 
small fraction of SUMO substrates detected in their sumoylated form at a given 
time (Dohmen, 2004). Therefore, it would be expected that mighty would be 
detected more strongly in its expected position (~25 kDa), than the 
approximately 50 kDa sumoylated form. It is possible that the mighty (peptide) 
antibodies are only detecting the sumoylated form due to possible 
conformational changes, but this is highly unlikely for mighty (bovine) 
antibodies which were raised against the entire mighty protein, and therefore 
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should have various mighty epitopes. So although it appears likely that mighty 
can be sumoylated, it seems unlikely that sumoylation is responsible for the 
apparent size difference observed by electrophoresis. Therefore phosphorylation 
appears to be the most likely reason to account for the migration difference 
observed with endogenous mighty protein.  
 
In addition to the large difference in apparent molecular weight of endogenous 
mighty protein, it was also shown to have a very different isoelectric point than 
expected by sequence data. The isoelectric point estimated by amino acid 
sequence data was pH 8.91, whereas the isoelectric point of endogenous mighty, 
as shown by isoelectric focusing (Fig 3.3), was approximately pH 5.7. Both 
phosphorylation and sumoylation can affect a protein’s net charge. Sumoylation 
structural analysis has shown that SUMO proteins possess a surface negative 
charge potential, so could alter the net charge of mighty (Huang et al., 2004). 
Unlike sumoylation, the effect of phosphorylation on the net charge of proteins 
has been well characterised. Phosphorylation influences a protein’s charge 
depending on the protein’s initial isoelectric point. By using ProMoST, the 
isoelectric point of mighty with 6 phosphorylations was given as pH 5.69. The 
negative charge of mighty would make it unlikely for mighty to bind to DNA 
directly. Therefore, if mighty does have a role in transcription, it would probably 
be in conjunction with another protein. It is also possible that mighty is inactive 
in its phosphorylated state and only binds to DNA when de-phosphorylated. 
This could possibly account for the approximately 30 kDa nuclear protein 
specifically seen in muscle extracts with mighty antibodies.  
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Two-dimensional electrophoresis showed a grouping of spots around the 45 to 
66 kDa range when incubated with mighty antibodies (peptide). However, none 
of these spots gave significant hits for mighty when analysed by mass 
spectrometry. Other proteins which occur abundantly were detected including 
tubulin, vimentin, and IgG. The inability to detect endogenous mighty by mass 
spectrometry was probably due to it being a protein of low abundance. Large 
differences in protein distribution in organisms and cells is recognised as a 
major limitation in the identification and characterisation of low-abundant 
proteins (Ahmed & Rice, 2005). The 2DE protein sample in this chapter was 
purified by nuclear extraction and isoelectric focusing. In addition, affinity 
chromatography was also attempted with 1DE electrophoresis which also did 
not achieve sufficient purity. Therefore, a more rigourous protein purification 
method will probably have to be developed to allow endogenous mighty to be 
examined by mass spectrometry. For example, Wang et al. (2005) described a 
combination of methods used to successfully identify and characterise 75 low 
abundant proteins from serum. Immunodepletion was used to remove high 
abundant proteins before the separation of proteins in three dimensions 
according to their charge, hydrophobicity, and molecular masses. The 
subsequent use of mass spectrometry allowed for the identification of proteins in 
the micro to femtomolar range.    
 
The MS results on the recombinant mighty proteins (mMty and bMty) showed a 
relatively small coverage of the entire protein sequence. This may be due to the 
inherent nature of the peptides resulting from the tryptic digest of the mighty 
protein. Not all peptides are easily detected by mass spectrometry. Small (<500 
Da), large (>3000 Da), and hydrophobic peptides are resistant to MS detection 
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(Gygi et al., 2000). This can significantly limit the peptides available for protein 
identification and characterisation. In addition, post-translational modifications 
can block sites of trypsin digestion and alter peptide masses resulting in 
unrecognisable peptides. Sensitive MS techniques can potentially identify post-
translationally modified peptides but requires very pure protein samples. 
Therefore, MS is a potentially powerful technique for protein identification and 
characterisation but has limitations with low abundant and post-translationally 
modified proteins. 
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CHAPTER FOUR 
MIGHTY EXPRESSION DURING MYOBLAST PROLIFERATION 
4.1   Introduction  
Proliferating myoblasts go through orderly stages of the cell-cycle to enable the 
accurate duplication of DNA and the subsequent division into two daughter 
cells. The cell-cycle, or cell division cycle, can be divided into four distinct 
stages: during the synthesis phase (S phase) the genetic material is copied 
faithfully; in the mitosis phase (M phase) the duplicated chromosomes are 
equally separated to the two daughter cells. The phases linking the S and M 
phases are gap-1 (G1) preceding the S phase and gap-2 (G2) preceding the M 
phase. The gap phases represent important regulatory check points and 
preparation for the following stage. During early G1, with the appropriate 
signals, a cell may withdraw from the cell-cycle into a resting quiescent state 
known as G0 or they may proceed to terminally differentiate (Tessema et al., 
2004).  
 
Cell cycle exit and early differentiation are closely linked processes that depend 
on the presence of growth factors. For differentiation to proceed, cell cycle 
arrest must occur, this happens during the G1 phase of the cell cycle. Signalling 
pathways during proliferation are suppressed to allow differentiation, for 
example, the inactivation of cyclin-dependent kinase (cdk) activity during G1/S 
by cyclin-dependent kinase inhibitors (CKI) such as p21, block cell cycle 
progression before the S phase permitting the differentiation pathway (Nadal-
Ginard, 1978; Clegg et al., 1987). 
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MyoD and Myf-5 are two myogenic proteins that have very different expression 
profiles during the myoblast cell-cycle. MyoD is low in G0 and is at its highest 
in G1; MyoD levels drop at G1/S and subsequently increase from S to M. In 
contrast, Myf-5 is at its highest in G0 and decreases dramatically during G1, 
reappears during G1/S and remains stable from S to M. This implies specific 
functions for MyoD and Myf-5 during the cell cycle and establishes a 
correlation between their ratios and the capacity of myoblasts to differentiate. 
This entry into differentiation occurs in G1, when myoblasts express high levels 
of MyoD, but not in G0 when cells express high levels of Myf-5 (Kitzmann et 
al., 1998). Cyclin A is another protein that has a characteristic expression pattern 
during the various phases of the cell cycle. Cyclin A is seen as an early marker 
of the S phase (Girard et al., 1991). Cyclin A increases during S phase and the 
levels decline before metaphase via ubiquitin-mediated proteolysis (Yam et al., 
2002). Therefore, MyoD, Myf-5, and cyclin A will be used as cell cycle markers 
in this chapter to examine the potential role of mighty in myoblast 
differentiation. 
 
Previous research in our laboratory on mighty overexpressing clones (Marshall, 
2005) has shown that overexpression of mighty in C2C12 cells does not alter the 
rate of proliferation or the duration of the cell cycle phases. The levels of mighty 
mRNA were similar in the G1, G1/S, and S phases of the cell cycle but reduced 
in the G0 phase. Myoblasts in G0 are considered to be quiescent and similar to a 
subset of myoblasts in culture referred to as reserve cells. Reserve cells express 
Myf-5 and CD34 and do not differentiate, but with the appropriate signals, are 
able to re-enter the cell cycle. Reserve cells are therefore often considered to be 
the in vitro equivalent of quiescent satellite cells in muscle tissue.  
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Hence to determine the role of mighty during proliferation, C2C12 myoblasts 
were synchronised to G0, G1, G1/S, S, and M according to the method of 
Kitzmann et al. (1998) and Western blotting was used to detect MyoD, Myf-5, 
and cyclin A protein during the cell cycle stages as markers for synchronisation. 
The levels of mighty protein expression at these cell cycle stages were then 
established to determine if mighty protein is differentially expressed during the 
cell cycle. In addition, mighty protein expression was detected by ICC during 
the cell cycle to compare with the Western results and to assess any possible 
spatial differences in mighty expression.    
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4.2  Materials and Methods 
4.2.1 C2C12 myoblast cell cycle synchronisation 
C2C12 myoblasts were seeded at a density of 15,000 cells/cm2 on 6-well plates 
(Nunc) to correspond to G0, G1, G1/S, S, and M stages of the cell cycle. Cells 
were left to attach overnight followed by the addition of DMEM (1 % (v/v) 
FCS) without methionine to all plates and incubated for 36 h. Protein from cells 
arrested in G0 was then extracted. Media was removed from the remaining 
plates and replaced with Proliferation Media (10 % FBS). After 1 h the media 
was removed from the G1/S, S, and M plates and replaced with Proliferation 
Media containing hydroxyurea (1 mM). After 3 h from the addition of 
Proliferation Medium, protein from the G1 plate was extracted. After 15 h from 
the addition of Proliferation Medium containing hydroxyurea, protein from the 
G1/S plate was extracted and the media changed to Proliferation Medium with 
the remaining S and M plates. Protein was extracted after 2 h for the S plate, and 
after 5 h for the M plate from the previous media change. Cells were harvested 
as in Section 2.2.2.5 and protein extracted as in Section 2.2.2.6. 
 
4.2.2 Western blotting 
Total protein (15 µg) was separated by SDS-PAGE (4-12% gradient, pre-cast 
gels, Invitrogen) and transferred to nitrocellulose membrane (Bio-Rad) by 
electroblotting as described in Section 2.2.5. The transferred membranes were 
blocked in 5% milk (w/v) in TBST at 4oC overnight. Primary antibody 
incubations were performed for 3 h at RT in 5% milk (w/v) in TBST at the 
following dilutions; MyoD, 1:400 dilution of a purified rabbit polyclonal anti-
MyoD antibody (sc-304; Santa Cruz Biotechnology, Inc.); Myf-5, 1:400 dilution 
of a purified rabbit polyclonal anti-Myf-5 antibody (sc-302; Santa Cruz 
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Biotechnology, Inc.); cyclin A, 1:400 dilution of a purified rabbit polyclonal 
anti-cyclin A antibody (sc-751; Santa Cruz Biotechnology, Inc.); GAPDH, 
1:5000 dilution of a purified mouse monoclonal anti-rabbit glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (RDI-TRK5G4-6C5; Research 
Diagnostics Incorporated). Following the incubation, the membranes were 
washed (5 X 5 min) with TBST. After washing, membranes were incubated with 
secondary antibody (1:2000) for 1 h at RT. Either anti-mouse IgG HRP 
conjugate (PO447; DakoCytomation) or anti-rabbit IgG HRP conjugate (PO448; 
DakoCytomation) was used depending on the primary antibody. The membranes 
were then washed (5 X 5 min) in TBST. HRP activity was then detected using 
Western Lightning (PerkinElmer) Western Blot Chemiluminescence Reagent. 
For the detection of mighty, the transferred membranes were blocked in a BSA 
buffer (0.3% BSA, 1% PVP, 1% PEG, TBST) for 3 h at RT to block non-
specific antibody binding. The blots were incubated with rabbit anti-mighty 
antibody (peptide) at 1:5000 dilution in BSA solution at 4°C overnight, with 
gentle shaking. Following the incubation, the membranes were washed (5 X 5 
min) with TBST. The membranes were then incubated with goat anti-rabbit 
conjugated to horseradish peroxidase (HRP) (Amersham) 1:2000 dilution in 
BSA solution for 1 h. Following washing (5 x 5 min in TBST), HRP activity 
was detected with ECL reagent (Western Lightning Chemiluminescense 
Reagent Plus). The bands were subsequently analysed by densitometry with a 
GS-800 Calibrated Densitometer (BioRad). 
 
4.2.3 Immunocytochemistry   
C2C12 cells were grown and synchronised as described in Section 4.2.1 in 
Permanox 4 well chamber slides (Invitrogen). After the appropriate 
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synchronisation treatment, the medium was removed and the cells washed once 
with 500 µl of PBS for 2 min. The cells were then fixed with 500 µl 20:2:1 (70% 
ethanol:formalin:acetic acid) per well for 30 s. The fixative was then removed 
and cells washed 3 x in PBS for 2 min with gentle shaking. The cells were then 
permeabolised with 0.5% Triton X-100 in PBS for 10 min at RT. Each well was 
then rinsed in 500 µl PBS. The cells were blocked with 5% BSA and 5% normal 
goat serum (NGS) in PBS for 4 h at RT with gentle shaking (300 µl/well). 
Following blocking, the cells were then washed 3 x PBS for 2 min with gentle 
shaking. Cells were incubated with mighty antibody (peptide) at 1:200 in 2.5% 
BSA and 2.5% NGS in PBS at 4oC with gentle shaking overnight (200 µl/well). 
After incubation, the cells were washed 3 x in TBST for 5 min with gentle 
shaking. The secondary antibody AF488 (A11008; Molecular Probes) was used 
at a 1:300 dilution in 2.5% BSA and 2.5% NGS in PBS, incubated for 1 h at RT 
with gentle shaking in the dark (200 µl/well). The cells were then washed 2 x 
with TBST for 5 min with gentle shaking in the dark (500 µl/well). Cells were 
mounted in Fluorescence Mounting Solution (DakoCytomation) and visualised 
by using green (WIB) filters with a U-ULH burner (Olympus Optical). 
Micrographs were taken using an Olympus BX50F microscope (Olympus 
Optical) and a spot RT™-KE slider camera (Diagnostics Instruments). 
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4.3 Results 
4.3.1 MyoD, Myf-5, and cyclin-A expression during the cell cycle 
MyoD and Myf-5 are two myogenic proteins that have very different expression 
profiles during the cell-cycle. The protein levels of MyoD, Myf-5, and cyclin A 
were examined by Western blotting in synchronised C2C12 myoblasts. As 
shown in Fig 4.1A, MyoD was at its lowest in G0 and highest in G1. Also as 
expected, MyoD levels decreased at G1/S and increased from S to M. Fig 4.1B 
shows Myf-5 to be at its highest in G0 and decreasing dramatically during G1. 
The levels of Myf-5 remained low throughout G1/S, S, and M phases. Fig 4.1C 
shows cyclin A expression which was very low in G0 and G1, then dramatically 
increased at G1/S and S phases as expected. However, cyclin A levels remained 
high during the M phase. 
 
4.3.2 Mighty expression during the cell cycle 
Fig 4.2 shows no significant difference between G0 and G1 in mighty protein 
expression. Compared with levels in G0 and G1, mighty protein expression was 
slightly higher during G1/S and M, and slightly lower in S phase. 
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Figure 4.1  Synchronisation of C2C12 myoblasts 
Western blots and corresponding bar-graphs of specific protein expression in 
C2C12 myoblasts synchronised at G0, G1, G1/S, S, and M stages of the cell 
cycle. Maximum expression was termed 1.0 and relative expression at various 
time points was plotted. Bars represent the relative mean ± SEM of three 
separate experiments with Westerns performed twice on each protein sample. 
GAPDH protein expression levels are provided to show even loadings. 
A, MyoD expression; B, Myf5 expression; C, Cyclin A expression. 
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Figure 4.2  Mighty expression during the cell cycle 
Western blot and corresponding bar-graph of mighty protein expression in 
C2C12 myoblasts synchronised at G0, G1, G1/S, S, and M stages of the cell 
cycle. Maximum expression was termed 1.0 and relative expression at various 
time points was plotted. Bars represent the relative mean ± SEM of three 
separate experiments with Westerns performed twice on each protein sample. 
GAPDH protein expression levels are provided to show even loadings. 
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4.3.3 Mighty expression during the cell cycle by immunocytochemistry  
Western blotting was previously used to quantitatively examine mighty 
expression at various stages of the cell cycle (Fig 4.2). Immunocytochemistry 
was also used to qualitatively examine the expression of mighty at G0, G1, 
G1/S, S, and M phases of the cell cycle (Fig 4.3).  Mighty distribution appeared 
to be perinuclear with lowest intensity seen in the G0 phase, whereas the highest 
intensity appeared to be in the G1/S phase of the cell cycle. In G1 and G1/S 
phases of the cell cycle, mighty also appeared to be localized to the golgi. 
Mighty expression in S and M phases appeared to be of similar intensity, 
however, mighty expression was diffuse in M phase and was detectable in the 
cytoplasm of the myoblasts.  
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Figure 4.3  Mighty expression during the cell cycle by ICC 
ICC micrographs from C2C12 myoblasts at G0, G1, G1/S, S, and M phases of 
the cell cycle using mighty antibody (pep) to detect endogenous mighty protein. 
Mighty antibody staining was visualised with an Alexa Fluor 488 conjugate. 
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4.4 Discussion  
In developing the synchronisation technique used in this study, Kitzmann et al., 
(1998) did various checks to validate its effectiveness. BrdU incorporation 
during DNA synthesis and antibodies were used to confirm the different stages 
of the cell cycle. To obtain myoblasts in a quiescent state (G0) without entry 
into differentiation, cells were grown in methionine-depleted medium. 
Methionine is an essential amino acid for growth but is not vital for cell viability 
(Nadal-Ginard, 1978). The commitment to quiescence is made near the end of 
the G1 phase; beyond this checkpoint, cells no longer respond to signals and 
complete their determined fate (Sherr, 2000). Therefore, cells should cycle until 
the G1 checkpoint where methionine depletion can trigger cell cycle exit and 
entry into quiescence. The cells grown in methionine-depleted medium by 
Kitzmann et al. (1998) did not incorporate BrdU and therefore appeared to be 
quiescent, and they also did not differentiate as shown by the lack of myogenin-
positive nuclei. Therefore, the method of methionine-deprivation appears to be 
effective to arrest myoblasts in a quiescent and non-differentiated state. These 
quiescent myoblasts are able to either proliferate or differentiate depending on 
the subsequent growth medium used. Once the quiescent myoblasts were placed 
in proliferation medium, the most ideal timepoints were ascertained for the 
various cell cycle phases. In addition, hydroxyurea (HU) was used to prevent 
DNA replication and synchronise cells at the G1/S boundary. This block by HU 
is fully reversible and allows cells to be further synchronised into the S phase. 
Using this method, Kitzmann et al. (1998) estimated the percentage of cells in 
the S phase to be >90% in a period less than 4 h, with a peak between 1 and 3 h 
(~70%) after HU release. After 6 h from HU release, ~40% of myoblasts were 
observed to enter mitosis. This is a high proportion, as mitosis only lasts <1 h in 
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the 20-22 h myoblast cell cycle after release from quiescence. Therefore, the 
synchronisation of C2C12 myoblasts by the double-block of G0-methionine 
deprivation and G1/S-HU blocking, appears to give insight to the G0, G1, G1/S, 
S, and M phases of the cell cycle. However, these phases are only enriched 
under the particular experimental conditions. It is expected that the G0, G1, and 
G1/S phases are the most highly enriched, whereas the S phase should be around 
70% enriched and the M phase around 40% enriched. The M phase would have 
the most potential to be missed as it only lasts <1 h. This may explain some of 
the slight variation seen in my results compared to Kitzmann et al. (1998), 
especially with cyclin A in the M phase. Overall, my results agreed with those 
shown by Kitzmann et al. (1998), allowing for determination of mighty protein 
expression during the cell cycle.  
 
The protein levels of mighty were not completely consistent between the 
Western and ICC results. The differences seen appeared to be in G0 and M, 
where low levels of mighty were seen by ICC compared by Western. These 
differences could be due to slight experimental variation with the 
synchronisation experiment, as they were performed at different times with 
different batches of components. Although these variations should be small, the 
short duration of the M phase could potentially alter the results. Another 
possible reason for variations between ICC and Western could be due to 
differences in the nature of the protein samples. With ICC, the protein is in a 
more ‘natural’ state in its cellular environment, whereas with Western blotting 
the protein is extracted from the lysed cells and denatured through treatment 
with SDS and β-mercaptoethanol. The possibility exists that interactions 
between mighty and other proteins could block antibody binding by ICC. The 
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separation of these protein interactions during Western blotting could potentially 
give different results. Also, differences in mighty cellular localisation were seen 
by ICC during the cell cycle. Mighty intensity appeared to be mainly perinuclear 
or localised to one side of the nucleus, indicating golgi localisation. This may be 
due to the addition of post-translational modifications occurring within the 
golgi. This is consistent with possible mighty phosphorylation occurring on 
newly synthesised protein during G1 and G1/S phases of the cell cycle.  
 
Taken together, the results from mighty mRNA and protein by ICC and Western 
appear to show mighty to be low in G0 and highest in G1/S. Low levels of 
mighty in G0 is consistent with the non-detection of mighty protein in quiescent 
satellite cells isolated from mouse muscle (unpublished results). Therefore, low 
levels of mighty during G0 (quiescence) may be due to high levels of myostatin 
present in G0 (McCroskey et al., 2003; Amthor et al., 2006) which may be 
required to keep cells in quiescence and stop myoblasts either proliferating or 
differentiating. Higher levels of mighty in G1/S could possibly correlate to the 
exit of myoblasts from the cell cycle to differentiate. This cell cycle exit is 
known to occur during G1 before the S phase, and is thought to involve 
increasing levels of MyoD during G1. Mighty is therefore possibly involved 
with the switch from proliferation to differentiation in myoblasts. 
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CHAPTER FIVE 
MIGHTY EXPRESSION DURING MYOBLAST DIFFERENTIATION 
5.1   Introduction 
Skeletal myogenesis was described by Andres and Walsh (1996) as a highly 
ordered process of temporally separable events that direct the transition from the 
proliferative myoblast to the terminally differentiated myotube. They showed 
that in vitro myogenesis, using C2C12 myoblasts, involved at least four 
temporally separable events: first, the entry of myoblasts into the differentiation 
pathway was indicated by the initiation of myogenin expression; second, the 
irreversible withdrawal from the cell cycle was indicated by the expression of 
p21; third, phenotypic differentiation was indicated by the induction of MHC; 
fourth, the fusion of differentiated myocytes to form myotubes. The significance 
of myogenin can be observed in myogenin KO mice, where deficient transcripts 
of various muscle-specific proteins is seen, including MHC, muscle creatine 
kinase, the alpha and gamma subunits of the acetylcholine receptor, and MRF4 
(Hasty et al., 1993). Once a myoblast enters the differentiation pathway, 
expresses myogenin and exits the cell cycle, it is committed to become skeletal 
muscle and is unable to proliferate. 
 
The differentiation of myoblasts is controlled by various factors. In cell culture 
experiments, differentiation of cells can be induced by depriving cycling 
myoblasts of serum, which results in the formation of committed myotubes. 
Myoblast differentiation is often viewed as being negatively regulated by 
medium components referred to as “mitogens.” However, stimulators of 
differentiation also occur, for example IGF-II is a secreted factor required for 
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terminal differentiation and is up-regulated upon transfer to low-serum 
differentiation medium, IGF-II can also enhance differentiation when added to 
media (Florini et al., 1991b).  
 
Various studies have shown myostatin to inhibit the differentiation of myoblasts 
in a dose dependent manner (Langley et al., 2002; Rios et al., 2002; Joulia et al., 
2003). In addition, Langley et al. (2002) showed this inhibition by myostatin to 
be reversible. Excess myostatin during differentiation inhibits the mRNA and 
protein levels of MyoD, myogenin, p21, and MHC, and inhibited the activity of 
creatine kinase (Langley et al., 2002; Rios et al., 2002). In agreement, Joulia et 
al. (2003) showed that overexpression of myostatin anti-sense upregulated 
MyoD mRNA and p21 protein levels. However, overexpression of MyoD did 
not rescue the myostatin induced inhibition of myoblast differentiation (Langley 
et al., 2002). 
 
A downstream target of myostatin, mighty appears to be a positive regulator of 
myoblast differentiation. Mighty overexpressing C2C12 myoblast clones have 
been shown to have enhanced differentiation (Marshall, 2005). This enhanced 
differentiation involves earlier formation of multinucleated myotubes and 
increased and earlier expression of myogenic differentiation markers MyoD, 
p21, myogenin, and MHC.  
 
This chapter aims to further investigate the role of mighty in differentiation of 
myoblasts. This will involve analysis of mighty expression during 
differentiation, firstly with C2C12 cells, and secondly with normal-muscle (NM) 
and double-muscle (DM) bovine primary myoblasts. The expression profile of 
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mighty will be established in these cells and compared with other proteins 
known to be involved in differentiation: MyoD, p21, myogenin, and MHC. 
Finally, the knockdown of mighty protein by RNAi will be investigated to 
examine the effect on MyoD, p21, and myogenin protein expression during 
differentiation.  
 
5.2  Materials and Methods 
5.2.1 C2C12 myoblast differentiation 
C2C12 myoblasts were plated on six-well plates in Proliferation Medium until 
approximately 70% confluent. The cells were then washed twice in PBS and 
Differentiation Medium (DMEM + 2% horse serum) added to the cells. The 
myoblasts were harvested as described in Secton 2.2.2.5 after 0, 2, 4, 6, 8, 12, 
24, 48, and 72 h time points after the addition of Differentiation Medium. The 
extraction of the protein from the cells was performed as outlined in Section 
2.2.2.6. 
 
5.2.2 Primary bovine myoblast (NM and DM) differentiation 
Bovine normal-muscle (NM) and double-muscle (DM) myoblasts were isolated 
by Mark Thomas (FMG, Ruakura) from day 90 foetal bovine muscle. The 
myoblasts were plated on 10 cm plates until approximately 70% confluent. The 
cells were then washed twice in PBS and Differentiation Medium (DMEM + 2% 
horse serum) added to the cells. The myoblasts were harvested by trypsinization 
as described in Section 2.2.2.4 after 0, 2, 4, 6, 8, 12, 24, and 48 h after the 
addition of Differentiation Medium. The extraction of the protein from the cells 
was performed as outlined in Section 2.2.2.6. 
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5.2.3 Mighty-siRNA treatment of C2C12 myoblasts during differentiation 
The effect of knocking down mighty expression was investigated using siRNA 
specifically targeted for mighty mRNA. Mighty-siRNA duplexes were procured 
from Qiagen which were designed using the HiPerformance Design Algorithim 
(Novartis AG), integrated with a stringency homology analysis tool. This was 
based on information from the mighty gene accession number 
(6330407G11Rik), locus ID (68050), and species (mouse). The target region for 
3HP is 1342-1362, and the target sequence is CTG CAA ATA CGT GGT GAG 
AAA. The mighty-siRNA was resuspended in 250 µl of Suspension Buffer 
(Qiagen) and heated to 90oC for 1 min. The resuspended siRNA (20 µM siRNA) 
was then incubated at 37oC for 1 h. A 2 µM working solution was made by 
further diluting an aliquot of 20 µM siRNA with Suspension Buffer. siRNA was 
stored at -20oC until required. 
 
C2C12 cells were plated and grown to 50-80% confluency at the time of 
transfection. Immediately prior to transfection, the medium was removed and 
the cells were washed once in 5 ml PBS. After the removal of the PBS, 2.3 ml of 
Differentiation Medium was added to each well. 5 nM siRNA was diluted in 
100 µl of DMEM (no serum), 5 µl of HiPerfect Transfection Reagent (Qiagen) 
was added to the diluted siRNA and mixed by vortexing. The siRNA was then 
incubated for 5-10 min at RT to allow the formation of transfection complexes. 
The siRNA complexes were then added dropwise to the appropriate wells. The 
plates were gently agitated to allow even distribution of the transfection 
complexes. The cells were then incubated for 48 h after transfection before the 
protein was extracted as in Section 2.2.2.6. Negative controls consisting of 
HiPerfect only and HiPerfect plus non-target siRNA were used. 
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5.2.4 Western blotting 
Total protein (15 µg) was separated by SDS-PAGE (4-12% gradient, pre-cast 
gels, Invitrogen) and transferred to nitrocellulose membrane (Bio-Rad) by 
electroblotting as described in Section 2.2.5. For the antibody incubations for 
mighty (Bovine), MyoD, myogenin, p21, MHC, and tubulin, the transferred 
membranes were blocked in 5% milk (w/v) in TBST at 4oC overnight. Primary 
antibody incubations were performed for 3 h at RT in 5% milk (w/v) in TBST at 
the following dilutions; Mighty (bovine), 1:2000 of purified rabbit polyclonal 
anti-mighty antibody (AgResearch); MyoD, 1:400 dilution of purified rabbit 
polyclonal anti-MyoD antibody (sc-304; Santa Cruz Biotechnology, Inc.); 
myogenin, 1:400 dilution of purified rabbit polyclonal anti-myogenin antibody 
(sc-576; Santa Cruz Biotechnology, Inc.); p21, 1:400 dilution of purified mouse 
monoclonal anti-p21 antibody (BD Biosciences Pharmingen); MHC (MF-20), 
1:1000 of purified rabbit polyclonal anti-MF-20 antibody (DSHB, University of 
Iowa); tubulin, 1:5000 dilution of purified mouse monoclonal anti-tubulin 
antibody (T-9026 clone DM 1A; Sigma). Following primary incubation, the 
membranes were washed (5 X 5 min) with TBST. After washing, membranes 
were incubated with secondary antibody (1:2000) for 1 h at RT. Either anti-
mouse IgG HRP conjugate (P0447; DakoCytomation) or anti-rabbit IgG HRP 
conjugate (P0448; DakoCytomation) was used depending on the primary 
antibody. The membranes were then washed (5 X 5 min) in TBST. HRP activity 
was then detected using Western Lightning (PerkinElmer) Western Blot 
Chemiluminescence Reagent. The antibody incubations using mighty (peptide) 
used a different buffer system. The transferred membranes were blocked in BSA 
solution (0.3% BSA, 1% PVP, 1% PEG, TBST) for 3 h at RT to block non-
specific antibody binding. Primary antibody incubation used rabbit anti-mighty 
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(peptide) antibody (QED Biosciences) 1:5000 dilution in BSA solution at 4°C 
overnight, with gentle shaking. Following primary incubation, the membranes 
were washed (5 X 5 min) with TBST. The membranes were then incubated with 
goat anti-rabbit conjugated to horseradish peroxidase (HRP) (Amersham) 
1:2000 dilution in BSA solution for 1 h.  Following washing (5 x 5 min in 
TBST), HRP activity was detected with ECL reagent (Western Lightning 
Chemiluminescense Reagent Plus). The bands were subsequently analysed by 
densitometry with a GS-800 Calibrated Densitometer (BioRad). 
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5.3 Results 
5.3.1 Expression profiles of MyoD, myogenin, p21, and MHC in C2C12 
myoblasts during differentiation 
The protein levels of MyoD, myogenin, p21, and MHC were monitored to check 
the efficiency of the differentiation experiment and to establish where mighty is 
expressed in the genetic hierarchy of differentiation. Fig 5.1 shows the 
expression profiles of MyoD, myogenin, p21, and MHC protein in C2C12 cells 
during differentiation. MyoD levels were first to increase at approximately 6-12 
h and peak at about 24 h. MyoD was also present in all the early timepoints at 
approximately one third the peak expression. This was expected as MyoD is 
involved in proliferation in addition to differentiation. Myogenin and p21 levels 
were the next to increase at approximately 12 h, with peak expression at about 
48 h. MHC levels followed, increasing at approximately 24 h with peak 
expression at about 72 h. Taken together, these results show the characteristic 
differentiation profile and allowed the subsequent comparison with mighty 
expression to be made. 
 
5.3.2 Expression profile of mighty in C2C12 myoblasts during differentiation 
Fig 5.2A shows the very early expression of mighty at approximately 4 h with 
peak expression at about 12 h. Like MyoD, mighty protein was present in 
proliferating myoblasts. There also appeared to be a decrease in mighty protein 
initially from 0 h to 4 h before increased expression was seen. Mighty protein 
levels also reduced to a basal level at 48 h. Fig 5.2B shows the relative 
expression of mighty compared to MyoD, myogenin, p21, and MHC. This 
figure shows that peak mighty expression appeared to be considerably earlier 
than the other proteins tested. 
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Figure 5.1  MyoD, myogenin, p21, and MHC expression during 
differentiation in C2C12 myoblasts 
Western blots and corresponding graphs of specific protein expression in C2C12 
myoblasts during differentiation. Maximum expression was termed 1.0 and 
relative expression at various time points was plotted. Each point represents the 
relative mean ± SEM of at least three separate experiments with Westerns 
performed twice on each protein sample. GAPDH protein expression levels are 
provided to show even loadings. 
A, MyoD expression; B, Myogenin expression; C, p21 expression; D, MHC 
expression. 
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Figure 5.2  Mighty expression during differentiation of C2C12 myoblasts 
Western blots and corresponding graphs of specific protein expression in C2C12 
myoblasts during differentiation. Maximum expression was termed 1.0 and 
relative expression at various time points was plotted. Each point represents the 
relative mean ± SEM of at least three separate experiments with Westerns 
performed twice on each protein sample. GAPDH protein expression levels, 
detected by anti-GAPDH antibodies, are provided to show even loadings. 
A, Mighty expression; B, Relative mighty expression compared with MyoD, 
myogenin, p21, and MHC. 
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5.3.3 NM and DM primary bovine myoblast differentiation 
As myostatin-null mice have increased levels of mighty, it was expected that 
DM bovine cells will have increased mighty and also show enhanced 
differentiation compared to NM bovine cells. Fig 5.3 shows NM and DM bovine 
cells during differentiation. The cells were counted before plating to ensure 
similar cell densities, and at the 0 timepoint there was no visible difference 
between NM and DM cells. At 6 h from the addition of Differentiation Medium, 
there were visibly more DM cells than NM cells. By 12 h, there were visibly 
more DM cells than NM cells. By 24 h, some myotubes were visible in the DM 
cells. There appeared to be no myotubes in the NM cells and they appeared to 
have a similar density as the DM cells at 12 h. At 48 h, some myotubes were 
present in the NM cells whereas the DM cells had many multi-branched 
myotubes. Fig 5.4 shows the Western blots and corresponding graphs from the 
protein taken from the cells shown in Fig 5.3. Increased expression was seen for 
mighty, MyoD, myogenin, and p21 in the DM cells compared to the NM cells. 
The largest increases were seen with MyoD and p21 which also peaked earlier 
in the DM cells than the NM cells. Both mighty and myogenin showed the same 
general pattern of expression between the NM and DM cells, but with higher 
levels seen in the DM compared to the NM cells. 
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Figure 5.3  Primary bovine myoblasts during differentiation (NM and DM) 
Representative brightfield image of NM and DM myoblasts after 0, 6, 12, 24, 
and 48 hrs in the differentiation medium. 
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Figure 5.4  Mighty, MyoD, myogenin, and p21 expression during 
differentiation in bovine myoblasts (NM and DM) 
Western blots and corresponding graphs of specific protein expression in 
primary bovine myoblasts (NM and DM) during differentiation. Maximum 
expression was termed 1.0 and relative expression at various time points was 
plotted. GAPDH protein expression levels are provided to show even loadings. 
A, Mighty expression; B, MyoD expression; C, Myogenin expression; D, p21 
expression. 
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5.3.4 Mighty-siRNA treatment of C2C12 myoblasts during differentiation 
RNA interference (RNAi) is a technique that knocks-down the expression of a 
protein by specifically degrading its mRNA. Fig 5.5A shows the knockdown of 
mighty protein expression by mighty-siRNA (Qiagen). The expression of 
mighty in C2C12 myoblasts transfected with mighty-siRNA was reduced by 
approximately 67% compared to cells transfected with non-target siRNA. A 
reduction in MyoD protein expression by approximately 31% was seen by 
mighty-siRNA (Fig 5.5B). Fig 5.5C shows an approximate 42% reduction in 
myogenin expression by mighty-siRNA, and Fig 5.5D showed that expression 
of p21 was reduced by approximately 34% by mighty-siRNA.  
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Figure 5.5  Mighty, MyoD, myogenin, and p21 expression in differentiating 
C2C12 myoblasts treated with mighty-siRNA 
Western blots and corresponding graphs of specific protein expression in C2C12 
myoblasts treated with mighty-siRNA compared to cells treated with non-target 
siRNA during differentiation. Control expression was termed 100 and relative 
expression of mighty-siRNA treated cells was plotted. Each point represents the 
relative mean ± SEM of at least three separate experiments. GAPDH protein 
expression levels are provided to show even loadings. Knockdown of mighty by 
mighty siRNA is significant by t-test (**p<0.005). The reduction of MyoD, 
myogenin, and p21 expression is also significant by t-test (*p<0.05). 
A, Mighty expression; B, MyoD expression; C, myogenin expression; D, p21 
expression. 
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5.4  Discussion 
The known positive inducers of myogenesis, such as insulin-like growth factors, 
enhance both MyoD expression and muscle differentiation (Pinset et al., 1988; 
Florini et al., 1991a; Albagli-Curiel et al., 1993; Carnac et al., 1993). 
Conversely, myostatin inhibits MyoD activity and expression resulting in the 
inhibition of myoblast differentiation (Langley et al., 2002). These results imply 
that a minimal level of MyoD must be reached before differentiation can be 
achieved. In agreement, MyoD levels have been observed to vary considerably 
in the nuclei of proliferating myoblasts by immunocytochemistry, whereas 
MyoD was seen to be homogeneously high in myotubes (Tapscott et al., 1988). 
During the terminal differentiation of skeletal myoblasts, MyoD appears to be 
upregulated before myogenin and p21, which are expressed in close succession. 
Andres & Walsh (1996) showed myogenin to be expressed before p21, as 
myogenin-positive cells remained capable of replicating DNA, whereas 
subsequent expression of p21 in differentiating myoblasts resulted in the post-
mitotic state. The appearance of structural proteins, such as myosin heavy chain 
(MHC) signals the phenotypic differentiation and subsequent fusion of 
differentiated myoblasts to form myotubes.  
 
To understand the role of mighty during muscle differentiation, the expression 
of mighty in C2C12 myoblasts was characterised. The differentiation profiles of 
MyoD, myogenin, p21, and MHC in this chapter (Figure 5.1) show the 
characteristic hierarchical expression during differentiation. The peak 
expression of mighty was at approximately 12 h, whereas MyoD expression 
peaked at approximately 24 h (Figure 5.2), indicating that mighty is possibly 
upstream of MyoD. In agreement, the knockdown of mighty by RNAi in C2C12 
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myoblasts reduced the levels of MyoD protein (Figure 5.5B). Subsequent 
reductions were also seen with myogenin and p21, indicating that the 
knockdown of mighty may affect the entire myoblast differentiation pathway. 
Although a large (67%) reduction in mighty protein was achieved through 
RNAi, not all cells would be transfected with mighty-siRNA. These non-
transfected cells would probably be producing normal amounts of IGF-II which 
is secreted into the medium. Therefore, even if transfected cells were not 
expressing mighty, they would still be receiving differentiation signals from 
other cells. So although significant reductions of differentiation markers were 
achieved using mighty-siRNA, extreme changes would not be expected. 
 
The role of mighty in differentiation has been predominately studied using 
mighty overexpressing clones derived from C2C12 myoblasts (Marshall, 2005). 
The use of primary myoblasts isolated from double muscle (DM) bovine 
muscle, gives an opportunity to study the effect of increased mighty expression 
through the non-functional myostatin seen in DM cattle. The comparison of DM 
to normal muscle (NM) cattle during differentiation offers a model which is 
similar to what is occurring in vivo to be examined. The myoblast images 
(Figure 5.3) clearly show the enhanced proliferation, and apparent enhanced 
differentiation, of the DM compared to the NM myoblasts. Figure 5.4 shows that 
higher levels of mighty in DM myoblasts corresponded with increased levels of 
MyoD, myogenin, and p21. There were especially large increases in MyoD and 
p21 protein levels, which also appeared to peak earlier in the DM compared to 
the NM cells. These results appear to show DM myoblasts to have enhanced 
differentiation, a phenotype seen in mighty overexpressing cells, which may be 
linked to mighty expression.  
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As mighty appears to be upregulated before MyoD, and the expression of MyoD 
is reduced by mighty-siRNA, mighty appears to be upstream of MyoD. 
However, Marshall (2005) has shown that mighty, through promoter analysis, 
does not directly increase the expression of MyoD. The direct effect of mighty 
on the p21 promoter was also investigated in a similar way and also does not 
appear to be directly regulated by mighty. Therefore, if mighty does upregulate 
MyoD expression during differentiaion, it would require an intermediate factor. 
Results by Marshall (2005) indicate this factor to be IGF-II. Increased IGF-II 
promoter activity, expression, and secretion were observed with mighty 
overexpression in C2C12 myoblasts along with an upregulation of the 
phosphatidylinositol 3-kinase (P13K) pathway. This pathway has been 
previously shown by Pinset et al. (1997) to participate in IGF receptor 
dependent differentiation of muscle cells after exposure to IGF-II, followed by 
the expression of MyoD and myogenin.  It has also been shown that IGF-II 
mRNA levels increase within a few hours of treatment of C2C12 cells with 2% 
horse serum (Florini et al., 1991b). Marshall (2005) also demonstrated that 
conditioned media taken from cultures of mighty overexpressing clones resulted 
in the enhanced differentiation of control cells in comparison to control 
conditioned medium. In agreement, the increased mighty mRNA seen in 
myostatin-null mice correlates with an increase in IGF-II mRNA in comparison 
to wild-type mice (Marshall, 2005). The mechanism of IGF-II mRNA 
upregulation by mighty overexpression was also investigated. No differences in 
mRNA stability were seen when actinomycin D, an inhibitor of RNA synthesis 
was used. However, mighty overexpression was shown to have an effect on 
IGF-II transcription through transient co-transfection with a mighty expression 
construct. Increased IGF-II promoter activity was observed in the presence of 
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mighty overexpression, but only with the HDAC inhibitor, TSA. HDAC 
proteins have histone deacetylase activity, and the resulting deacetylation of 
histones prevents transcription factor access to DNA through more compact 
chromatin (Mal et al., 2001). Therefore, mighty appears to upregulate IGF-II 
expression in a HDAC dependent manner resulting in enhanced myogenic 
differentiation through the upregulation of MyoD expression 
 
The stage where mighty appears to be upregulated may involve the transition 
from proliferation to differentiation in myoblasts. Although mighty does not 
appear to be involved with the increased proliferation seen in myostatin-null 
animals, it may be an important factor in initiating myoblast differentiation. This 
gives mighty promise for treating muscle disorders where impaired 
differentiation is seen. For example, sarcopenia in aged muscle appears to be not 
only due to a limitation of satellite cells to proliferate, but also to their weakened 
capability to differentiate (Lorenzon et al., 2004; Bortoli et al., 2005). 
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CHAPTER SIX 
FINAL DISCUSSION AND FUTURE DIRECTIONS 
Mighty was originally discovered through the presence of higher levels of 
mighty mRNA in the muscle of myostatin-null mice compared to wild-type 
mice. Thus the role of mighty was investigated to determine its possible function 
in the myostatin-null phenotype. Results from this thesis appear to show that 
mighty plays an early role in myogenic differentiation. This role in 
differentiation appears to be upstream of MyoD through the upregulation of 
IGF-II and may be linked to cell cycle exit in the G1 phase of the cell cycle. 
Therefore, mighty may be involved in the enhanced differentiation seen in 
myostatin-null animals. Future work could use transgenic animals to further 
investigate the role of mighty in myogenesis. Transgenic animals could be 
generated to examine the effect of mighty overexpression and removal (mighty-
null). Although experiments using C. elegans indicate that mighty removal is 
lethal, the success of RNAi in this study could be further enhanced by 
constructing stably producing mighty-siRNA mutants. This could enable full 
knockdown of mighty expression, in addition, mighty knockdown at specific 
stages could be investigated through an inducible mighty-siRNA promoter. The 
use of a muscle-specific promoter could also allow the investigation of mighty 
knockdown specifically in skeletal muscle.  
 
The characterisation of the mighty protein revealed it to be a low-abundant 
nuclear protein which appears to be regulated by phosphorylation and 
sumoylation. The large difference in apparent molecular weight and charge of 
endogenous mighty protein, in addition to mighty sequence data, indicate that 
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endogenous mighty exists in a phosphorylated form (~52 kDa) during myoblast 
proliferation and differentiation. Interestingly, this 52 kDa form was not 
detected in muscle tissue, but a specific band was detected at ~30 kDa in nuclear 
extracts from muscle tissue. In addition, there also appeared to be more of this 
30 kDa protein in myostatin-null muscle compared to control muscle. Therefore, 
the 30 kDa protein may be mighty in a hypophosphorylated form, possibly 
indicating a different function for mighty in fully-differentiated muscle 
compared to proliferating and differentiating myoblasts. The fact that mighty is 
a nuclear protein, of low-abundance, and contains a possible forkhead 
transcription-factor domain, appears to indicate that mighty acts as a 
transcription factor. However, the negative charge of 52 kDa mighty makes 
binding to DNA unlikely in this form. This raises the possibility that the 30 kDa 
hypophosphorylated form of mighty is active in muscle tissue through being 
positively charged, enabling DNA binding. However, as the levels of 52 kDa 
mighty were seen to increase, and subsequently decrease, during the early stages 
of differentiation, it is unlikely that the 52 kDa form is inactive. A more likely 
possibility is that 52 kDa mighty exerts its effects on transcription by forming a 
protein complex with another protein/s. As mighty overexpression in C2C12 
myoblasts increases IGF-II promoter activity (Marshall, 2005), a direct 
interaction between mighty and DNA appears to be occurring. 
 
To investigate the possibility of the interaction of mighty with other proteins, 
various techniques could be employed. Western blotting could be performed 
under non-denaturing conditions to indicate if mighty is associated with another 
protein. The yeast two-hybrid assay could be used to assess the potential binding 
of mighty, but would be limited to the use of known proteins. Recombinant 
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mighty protein (rMty) may also allow the binding and subsequent isolation of an 
interacting protein. The use of rMty would be preferred due to the ease of 
isolating large amounts of relatively pure rMty in comparison to endogenous 
mighty. If sufficient quantities of pure endogenous protein are required, a robust 
purification method will need to be developed. This may require methods to 
remove abundant proteins, such as immunoprecipitation, and subsequent use of 
‘high performance liquid chromatography’ (HPLC) methods to successfully 
isolate endogenous mighty protein from complex cellular lysates. Pure 
endogenous mighty should allow for robust MS analysis, potentially allowing 
for the identification of post-translational modifications (PTMs). The mighty 
gene could also be manipulated with the use of truncations and mutations of 
possible PTM sites. This could potentially give valuable information on PTMs 
and potential protein interactions. Also, the high probability of mighty 
sumoylation merits further investigation.    
 
In conclusion, results in this thesis indicate that mighty plays an early role in 
myogenic differentiation. Although insights were gained through mighty 
characterisation studies, more work is required to fully understand the function 
of mighty in myogenesis. Mighty may play an important role postnatally by 
enabling satellite cells to differentiate in repairing or growing muscle. This 
could be potentially a target for therapies where inadequate muscle repair occurs 
through the lack of myoblast differentiation into myotubes and subsequent 
muscle fibres.  
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